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Executive Summary 
Introduction 
Health Problem 
Treatment-resistant hypertension (TRH) is defined as blood pressure (BP) 
that remains above goal despite adhering to the maximally tolerated doses of 
three antihypertensive drugs with complementary mechanism of action, and 
including one diuretic agent. Hypertension, especially if not controlled, is a 
leading cause of cardiovascular and renal diseases and it increases the risk for 
stroke, coronary artery disease, arrhythmias, and heart-, and renal failure. Hy-
pertension is usually asymptomatic, and treatment adherence is one major 
obstacle to the successful control of BP.  
Other causes for uncontrolled hypertension need to be ruled out, in order to 
correctly diagnose a patient with TRH. The most common underlying reasons 
for uncontrolled hypertension are poor adherence to anti-hypertensive treat-
ment, inaccurate or suboptimal therapy or BP measurements, and pseudo-
elevated BP due to white-coat effect. Furthermore, secondary causes of hyper-
tension, such as primary aldosteronism and renal artery stenosis, should be 
considered. The adequate diagnostic approach includes 24-hours ambulatory 
blood pressure measurements (AMBP) to rule out white-coat hypertension. 
First-line therapy of TRH includes lifestyle modifications, such as diet and 
exercise and a combination of anti-hypertensive medicines, such as an ACE-
inhibitor, a calcium channel blocker and a diuretic. 
The actual prevalence of TRH is unknown and controversially discussed. A 
wide variability exists in the reported prevalence ranging from 2% to 30% of 
hypertensive patients [3], depending on the population examined [4]. In a re-
cent Austrian cross-sectional multicentre study on 4,303 patients with hyper-
tension, BP remained uncontrolled in more than 50% of patients (defined as 
<140/90 mmHg office BP).  
Description of technology 
Baroreceptor activation therapy (BAT) is a treatment option proposed for pa-
tients with TRH. The BAT aims to reduce BP by electrically stimulating the 
carotid baroreflex, which acts on the sympathetic and parasympathetic nerv-
ous system. The Barostim neo™, a second-generation device for BAT, is cur-
rently the only available CE-marketed device that activates the baroreceptor 
reflex by electric impulses. The first generation device Rheos® system is not 
marketed anymore and has been entirely replaced by the second generation.  
The two generations of devices feature major differences: the Barostim neo™ 
consists of a smaller electrode, and a smaller pulse generator with a longer 
battery life, the electrode is placed unilaterally on only one carotid sinus, and 
thus the surgical procedure is simpler and shorter, requiring less recovery 
time. Due to these substantial differences, pooling of efficacy and safety data 
of both devices would not be sensible.  
Other technologies exist targeting the baroreceptors (MobiusHD®) or the sym-
pathetic system to lower BP (renal denervation), however, effectiveness and 
safety of these procedures have not yet been established.  
 
TRH: BP above 
140/90mmHg despite  
3 or more  
anti-hypertensive 
medicines 
other causes  
for uncontrolled 
hypertension need to  
be excluded: Pseudo-
resistant hypertension, 
secondary hypertension, 
white-coat hypertension 
unknown prevalence : 
ranging from 2%-30% 
of patients with 
diagnosed hypertension 
BAT: reduction of BP  
by electric stimulation 
of baroreceptors  
 
2 devices: Barostim 
neo™ and Rheos® 
system, the latter not 
marketed anymore 
 
major differences 
between the  
2 generation-devices 
other emerging 
technologies  
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Methods 
The aim of this report was to assess effectiveness and safety of the BAT to 
decrease BP and reduce the number of cardiovascular events as compared to 
standard therapy. A systematic literature search was performed in December 
2017 in four databases (Cochrane Library, Centre for Research and Dissem-
ination, Embase, Medline), complemented by a hand search in the reference 
list of relevant studies. In addition, clinical trials databases were searched to 
identify non-published results and ongoing studies. Overall, 416 citations were 
identified, of which 63 were assessed for full text review, and finally seven 
were selected for the qualitative synthesis.  
The IHE-20-checklist was used in order to assess the risk of bias (RoB) for 
case series, the Cochrane RoB tool was applied to check the RoB of RCTs. 
The quality of the body of evidence was assessed using GRADE (Grading of 
Recommendations, Assessment, Development and Evaluation).  
Studies with retrospective study design, and case series with less than 20 
patients enrolled were excluded.  
 
Results 
Available evidence 
For the second-generation device, the Barostim neo™, three case series with 
a total of 106 patients were identified [5-7], and one randomised, controlled 
crossover trial on 16 patients [8]. The latter assessed the effects of treatment 
withdrawal of BAT within an 8-week period, but did not include outcomes 
related to device safety.  
We identified one comparative study, which compared BAT with a sham pro-
cedure: an RCT on the first generation device on 265 patients [9].  
For the first generation device, two additional studies were included, one 
long-term open label follow up on the RCT [10], and one case series on 45 
patients [11]. Evidence from the first generation device was not considered 
relevant for the recommendation, as the device is no longer available on the 
market and differs substantially from the second-generation device.  
Clinical effectiveness 
For the second-generation device, no evidence was available comparing BAT 
to the sham procedure, or BAT to standard therapy.  
One case series on the second generation device (n=44) measured a decrease 
of BP by means of 24-hours AMBP. They reported an average decrease in 
SBP by 8 mmHg. A reduction of at least 5 mmHg was not achieved in 20 of 
44 patients (45%) [5]. 
The RCT on the first generation device reported no significant difference in 
systolic BP (SBP) within the two groups after a follow-up period of 6 months 
(54% in the interventional group, to 46% in the sham group, p> 0.005, office 
BP measurement) [9]. 
No evidence was available comparing the number of cardiovascular events in 
patients receiving BAT versus standard therapy.  
From the available evidence, no conclusion on the clinical effectiveness of 
BAT can be drawn, and the quality of evidence was considered very low.  
sytematic review in  
4 databases, and  
hand search 
 
416 publikations,  
63 for fulltext analysis,  
7 selected for review 
risk of bias and quality 
of evidence assed  
with tools 
exclusion of 
retrospective study 
design, case series < 20  
Barostim neo™:  
3 case series (N=106),  
1 cross-sectional study 
(N=16) 
RCT on Rheos® system 
(N=265) 
evidence from Rheos® 
system not considered 
for recommendation 
clinical effectiveness: 
 
no studies comparing 
BAT to standard therapy,  
BAT to sham procedure 
only for Rheos® system: 
no significant BP 
differences after  
6 months follow-up 
no evidence on 
reduction of 
cardiovascular events 
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Safety 
No studies comparing safety of BAT to standard therapy were available.  
The only comparative data to evaluate safety was derived from the RCT on 
the first generation device, the Rheos pivotal trial [12], which reported 68 
procedural complications (13 surgical complications, 13 nerve injuries with 
residual effect, 12 temporary nerve injuries, 7 respiratory complications, 7 
wound complications). Furthermore, 34 device-related adverse events were re-
ported, of which six were hypertension-related strokes. Five of the 265 pa-
tients had their device removed during the 12 months follow up time. With-
in the six years follow-up, de Leeuw et al. 2017 reported 335 serious adverse 
events (SAEs) occurring in 111 patients, of which 26 SAEs (23%) were direct-
ly related to the procedure or BAT system [10]. 
For the second generation device, safety outcomes were reported by two case 
series for a total patient population of 74 patients [7]. In total, 23 procedural 
AE (surgical complications, device pocket haematoma, pain near the device 
site, wound healing complication) and three SAEs were reported (one hyper-
tension-related stroke, one movement of the IPG, one serious wound healing 
defect). Within the six months follow-up, none of the second-generation de-
vices needed to be explanted. 
The quality of evidence is very low.  
Upcoming evidence 
Three ongoing RCTs on the BAT were identified: 
 The Barostim neo™ Pivotal Trial (n=310), a non-blinded RCT com-
paring BAT to standard management, has a completion date of Sep-
tember 2017, results are still pending.  
 The Nordic BAT Study (n=100) is a double-blinded RCT comparing 
BAT to the sham procedure. Its primary completing date is November 
2020.  
 The ESTIM-rHTN trial (n=128), a randomised medico-economic 
study that assesses economic efficacy of BAT compared to standard 
therapy. This is the first evaluation of BAT compared to standard ther-
apy, which includes a comparison of the number of CV events, yet as 
secondary outcome measure.  
In addition to the indication of TRH, BAT is currently evaluated as thera-
peutic option in patients with heart failure (NYHA Class III). The pivotal 
trial of Barostim Therapy for Heart Failure (BeAT-HF) enrolled 800 partic-
ipants and aims at FDA approval (estimated completion date 2021).  
Reimbursement 
BAT is currently not included in the Austrian benefit catalogue.  
Estimated treatment costs for the implantation are at 3,500 Euros, the Barost-
im neo™ system costs 21,000 Euros, and the battery costs are 15,000 Euros if 
replacement is needed [13]. 
 
no studies comparing 
BAT to standard therapy 
 
Rheos pivotal trial:  
68 procedural 
complications,  
34 device-related-
adverse events 
Barostim neo™:  
less adverse events,  
no device explanations  
ongoing studies 
ongoing study assessing 
BAT as treatment for 
heart failure 
not included in Austrian 
benefit catalogue 
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Conclusion 
Substantial evidence proving the efficacy and safety of BAT is limited. For 
the second-generation device, no controlled studies are available to date that 
compared BAT to sham procedure or BAT to standard management (infor-
mation confirmed by manufacturers), despite being the only BAT device avail-
able on the market.  
The small patient population, lacking control groups and blinding, and the 
paucity of studies on the second-generation device contribute to an overall 
very low quality of evidence, for both efficacy and safety-related outcomes. 
All of the studies were either directly funded by the manufacturer, or first 
authors received study grants or consultancy fees. No independently con-
ducted study could be identified. Importantly, the most crucial outcome of a 
reduction in the number of cardiovascular events as compared to standard 
therapy was not assessed by any of the studies.  
A major obstacle to control hypertension is poor adherence to hypertensive 
therapy. Therapy adherence is seldomly assessed during the cause of a clini-
cal trial, and if, mostly by means of patient-reported questionnaires rather 
than urine analysis or other objective measures. An increase or decrease in 
therapy adherence during the trials could thus be a major confounder of the 
trial results.  
BAT has not conclusively provided robust evidence for its benefit and safety. 
By contrast, the only comparative data on the first generation device was not 
able to establish a meaningful benefit for patients. Future clinical trials should 
assess BP reduction based on AMBP measurements, and include monitoring 
of therapy adherence. More importantly, apart from a reduction in BP emerg-
ing technologies on TRH need to prove if they provide a benefit in the long-
term reduction of CV events.  
 
Recommendation 
BAT is currently not recommended for inclusion in the Austrian benefit cat-
alogue due to insufficient evidence.  
  
no sufficient evidence  
to conclude on 
effectiveness or safety 
of BAT 
low quality of evidence 
due to small sample 
sizes, lacking blinding, 
and control group 
therapy adherence not 
assessed by most studies 
future studies shall 
assess BP reduction 
based on AMBP 
measurements, monitor 
therapy adherence,  
and assess differences  
in the number of 
cardiovascular events 
inclusion currently  
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Therapieresistenter Bluthochdruck (TRH) ist definiert als Blutdruck (BD), 
der über dem Zielwert von 140/90 mmHg bleibt, trotz Einhaltung der maxi-
mal tolerierten Dosen von drei blutdrucksenkenden Medikamenten mit kom-
plementärem Wirkungsmechanismus inklusive eines Diuretikums. Bluthoch-
druck, insbesondere unkontrollierter Bluthochdruck, ist eine der Hauptursa-
chen für Herz-Kreislauf- und Nierenerkrankungen und erhöht das Risiko für 
Schlaganfälle, koronare Herzkrankheiten, Herzrhythmusstörungen sowie Herz- 
und Nierenversagen. Bluthochdruck ist in der Regel asymptomatisch. Thera-
pieadhärenz spielt deshalb eine entscheidende Rolle für den Therapieerfolg.  
Für die Diagnose TRH müssen zunächst andere Ursachen für unkontrollierte 
Hypertonie ausgeschlossen werden: Pseudoresistente Hypertonie und Weiß-
kittelhypertonie zählen zu den häufigsten Ursachen für unkontrollierten Blut-
hochdruck. Mangelnde Therapieadhärenz, eine suboptimale Therapie, oder 
ungenaue Blutdruckmessungen sind oft ursächlich für die sogenannte Pseu-
doresistenz. Des Weiteren sollten sekundäre Ursachen für Bluthochdruck er-
wogen werden, wie primärer Aldosteronismus und Nierenarterienstenose. Der 
diagnostische Ansatz umfasst eine 24-stündige ambulante Blutdruckmessung 
(AMBP), um Weißkittelhypertonie auszuschließen. Die First-Line-Therapie 
der TRH besteht in einer Lebensstilmodifikation, z. B. Diät, sowie einer Kom-
binationstherapie mehrerer blutdrucksenkender Medikamente (anfänglich zu-
meist einem ACE-Hemmer, einem Kalziumkanalblocker und einem Diureti-
kum). 
Die Prävalenz von TRH ist nicht bekannt, und liegt, abhängig von der un-
tersuchten Population [3], zwischen 2 % und 30 % der hypertensiven Patien-
tInnen [4]. In einer rezenten multizentrischen Querschnittsstudie an 4.303 
österreichischen HypertonikerInnen blieb der Blutdruck bei mehr als 50 % 
der PatientInnen unkontrolliert (definiert als <140/90 mmHg).  
Beschreibung der Technologie 
Die Barorezeptortherapie (BAT) ist eine alternative Behandlungsoption für 
PatientInnen mit TRH. Durch Aktivierung des Baroreflexes mittels elektri-
scher Impulse zielt BAT darauf ab den Blutdruck zu reduzieren. Durch die 
Stimulation der Barorezeptoren soll eine Aktivierung des Parasympathikus 
und Deaktivierung des Sympathikus erreicht werden, was in weiterer Folge 
eine Senkung des Blutdrucks bewirkt. Derzeit ist nur ein Produkt der zweiten 
Generation der BAT-Produkte zugelassen, der Barostim neo™. Das Rheos®-
System, das Produkt der ersten Generation, ist nicht mehr erhältlich und 
wurde gänzlich durch die neue Generation ersetzt. 
Das Vorgänger und Folgeprodukt unterschieden sich wesentlich in ihrem Auf-
bau, und dem Implantationsprozedere: der Barostim neo™ besteht aus einer 
kleineren Elektrode, einem kleineren Pulsgenerator mit einer längeren Batte-
rielebensdauer. Die Elektrode wird einseitig auf nur einem Karotissinus plat-
ziert und somit ist der chirurgische Eingriff einfacher und kürzer, und erfor-
dert kürzere Rehabilitation. Aufgrund dieser wesentlichen Unterschiede wur-
den Wirksamkeits- und Sicherheitsdaten beider Produkte getrennt bewertet.  
Definition 
therapieresistente 
Hypertonie (TRH) 
Diagnose: Ausschluss 
anderer Ursachen,  
24-h Blutdruckmessung 
Prävalenz nicht 
bekannt: von 2 %-30 % 
der PatientInnen mit 
diagnostizierter 
Hypertonie 
BAT: Stimulation der 
Barorezeptoren zur 
Senkung des BD 
 
zwei Produkte:  
Barostim neo™ und 
Rheos®-System 
Rheos®-System: derzeit 
nicht mehr verfügbar, 
und mit Barostim neo™ 
ersetzt 
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Weitere Technologien, die auf die Barorezeptoren (MobiusHD®) oder das 
Sympathikus-System zur Senkung des Blutdrucks (renale Denervation) ab-
zielen, werden derzeit innerhalb von Studien untersucht, ihre Wirksamkeit 
und Sicherheit ist jedoch noch nicht erwiesen. 
 
Methoden 
Ziel dieses Berichts war es, die Wirksamkeit und Sicherheit der BAT zur 
Senkung des Blutdrucks und zur Verringerung der Anzahl kardiovaskulärer 
Ereignisse im Vergleich zur Standardtherapie zu bewerten. Eine systemati-
sche Literaturrecherche wurde im Dezember 2017 in vier Datenbanken (Coch-
rane Library, Zentrum für Forschung und Dissemination, Embase, Medline) 
durchgeführt, ergänzt durch eine Handsuche in der Referenzliste relevanter 
Studien. Darüber hinaus wurden Datenbanken für klinische Studien durch-
sucht, um nicht-veröffentlichte Ergebnisse und laufende Studien zu identi-
fizieren. Insgesamt wurden 416 Zitate identifiziert, von denen 63 Volltexte 
analysiert und schließlich sieben für die qualitative Synthese ausgewählt 
wurden. 
Das Bias-Risiko (RoB) auf Studienebene wurde für Fallserien mit der IHE-
20-Checkliste bewertet, für randomisierten kontrollierten Studien mit dem 
Cochrane RoB-Tool. Die Qualität der Evidenz wurde mit GRADE bewertet. 
Studien mit retrospektivem Studiendesign und Fallserien mit weniger als 20 
eingeschlossenen PatientInnen wurden ausgeschlossen. 
 
Ergebnisse 
Verfügbare Evidenz 
Für das Produkt der zweiten Generation, Barostim neo™, wurden drei Fall-
serien mit insgesamt 106 PatientInnen und eine randomisierte, kontrollierte 
Cross-Over-Studie an 16 PatientInnen identifiziert. Letztere bewertete die 
Auswirkungen eines Therapieabbruchs bei der Behandlung mit BAT in ei-
nem Zeitraum von 8 Wochen. 
Insgesamt konnte eine Vergleichsstudie identifiziert werden die BAT mit ei-
nem Scheinverfahren vergleicht: das Rheos pivotal trial an 265 PatientInnen. 
Für das Rheos® system wurden zusätzlich zwei weitere Studien eingeschlos-
sen, eine langfristige Open-Label-Follow-up des RCT und eine Fallserie mit 
45 PatientInnen. Wirksamkeits- und Sicherheitsdaten dieses Produktes wur-
den für die Empfehlung als nicht relevant angesehen, da es nicht mehr er-
hältlich ist, zur Gänze mit dem Barostim neo™ ausgetauscht wurde und sich 
zu diesem wesentlich unterscheidet. 
Klinische Wirksamkeit 
Für Barostim neo™ lagen keine Vergleichsstudien vor, um die Wirksamkeit 
von BAT im Vergleich zu einem Scheinverfahren oder zur Standardtherapie 
zu beurteilen.  
Eine Fallserie (n=44) zum Barostim neo™ berichtete eine Verringerung des 
24-Stunden Blutdrucks, mit einer durchschnittlichen Abnahme des systoli-
schen Blutdrucks um 8 mmHg. Eine Reduktion von mindestens 5 mmHg wur-
de bei 20 von 44 PatientInnen (45 %) nicht erreicht [5]. Die verbleibenden 
beiden Fallserien berichten diesen Endpunkt nicht und es erfolgte eine Mes-
sung der Blutdruckreduktion mittels Office-Blutdruckmessungen. 
andere Technologien  
zur Behandlung der TRH 
derzeit in klinischen 
Studien 
systematische 
Literatursuche und 
Handsuche in  
4 Datenbanken 
 
Bias-Risiko mit  
IHE Checkliste und  
Cochrane RoB tool 
Qualität der Evidenz  
mit GRADE 
insgesamt 4 Studien  
zu Barostim neo™:  
106 PatientInnen in  
3 Fallserien,  
16 PatientInnen in 
Cross-over Studie 
3 Studien zum 
Vorgängermodell 
Rheos® system – jedoch 
keine GRADE-
Bewertung/ 
Empfehlungen 
Barostim neo™:  
keine Vergleichsstudien 
zur Standard- oder 
Scheintherapie 
 
eine Fallserie zur 
Senkung des 24h BD: 
durchschnittlich  
8 mmHg 
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Das RCT zum Erstprodukt Rheos® system zeigte keinen signifikanten Unter-
schied in den systolischen Blutdruckwerten zwischen der Interventions- und 
der Scheingruppe nach einer Beobachtungszeit von sechs Monaten (54 % in 
der Interventionsgruppe, 46 % in der Scheingruppe, p>0,005, Office-Blut-
druckmessung).  
Es liegen keine Studienergebnisse zur Reduktion der Anzahl an kardiovasku-
lären Ereignissen im Vergleich zur Standardtherapie vor.  
Aus der verfügbaren Evidenz lassen sich keine Schlussfolgerungen zur klini-
schen Wirksamkeit der BAT ableiten. Die Qualität der Evidenz wurde als sehr 
gering ermessen. 
Sicherheit 
Die einzigen Vergleichsdaten zur Bewertung der Sicherheit stammten aus der 
RCT der Erstgeneration, der Rheos-Zulassungsstudie [6], die über 68 operati-
ve Komplikationen berichteten (13 chirurgische Komplikationen, 13 bleibende 
Nervenverletzungen, 12 temporäre Nervenverletzungen, 7 respiratorische Kom-
plikationen, 7 Wundkomplikationen). Darüber hinaus wurden 34 Produkt-
assoziierte unerwünschte Ereignisse berichtet, von denen sechs Bluthoch-
druckbedingte Schlaganfälle waren. Bei fünf der 265 PatientInnen wurde das 
Implantat während der 12-monatigen Nachbeobachtungszeit entfernt. In der 
Langzeit-Beobachtungsstudie wurden nach sechs Jahren 335 schwere uner-
wünschte Ereignisse bei 111 Patienten erhoben, von denen 26 (23 %) direkt 
mit dem Verfahren oder BAT-System in Zusammenhang standen.  
Zwei Fallserien berichten Endpunkte zur Bewertung der Sicherheit von Ba-
rostim neo™ für eine Gesamtpopulation von 74 PatientInnen. Insgesamt wur-
den 23 unerwünschte Nebenwirkungen (chirurgische Komplikationen, Hä-
matom, Schmerzen, Wundheilungskomplikationen) und drei schwere uner-
wünschte Nebenwirkungen (Bluthochdruck bedingter Schlaganfall, Bewegung 
des IPG, schwerer Wundheilungsdefekt) berichtet. Innerhalb der Nachunter-
suchung von sechs Monaten musste keines der Geräte der zweiten Generation 
explantiert werden. Die Qualität der Evidenz wurde als sehr gering erachtet.  
Laufende Studien 
Derzeit laufen drei randomisierte, kontrollierte Studien zum BAT-Verfahren:  
 Barostim neo™ Zulassungsstudie (n=310), ein nicht-verblindetes RCT, 
welches BAT mit der Standardtherapie vergleicht. Fertigstellung sollte 
im September 2017 stattfinden, die Ergebnisse stehen derzeit noch aus. 
 Nordic BAT Study (n=100), ein doppelt-verblindetes RCT, das BAT 
zur Scheinprozedur vergleicht. Die Fertigstellung ist für November 
2020 angedacht.  
 ESTIM-rHTN Trial (n=128), eine randomisierte-ökonomische Studie, 
die neben Wirksamkeit und Sicherheit auch Kosteneffizienz der BAT 
untersucht. BAT wird hierbei mit der Standardtherapie verglichen. 
Diese Studie beinhaltet erstmalig den Endpunkt “Reduktion in der 
Anzahl an kardiovaskulären Events“, allerdings als sekundären End-
punkt.  
Neben der Indikation TRH wird die BAT derzeit als Therapieoption bei Pa-
tientInnen mit Herzinsuffizienz (NYHA-Klasse III) evaluiert. Die Zulassungs-
studie zur BAT bei Herzinsuffizienz (BeAT-HF) umfasst 800 TeilnehmerIn-
nen und zielt auf eine FDA-Zulassung ab (geschätzte Fertigstellung 2021). 
RCT zu Rheos® system: 
keine signifikanten 
Unterschiede zw 
Interventions- und 
Kontrollgruppe 
keine Studie berichtet 
zu kardiovaskuläre 
Ereignissen 
 
Qualität der Evidenz 
sehr niedrig 
Vergleichsdaten zur 
Sicherheit aus Rheos 
RCT: 68 operative 
Komplikationen,  
34 unerwünschte NW 
 
6 Jahres-Follow-up:  
335 schwere NW in  
111 PatientInnen, davon 
26 BAT-bezogene 
schwere NW  
2 Fallserien berichten 
bzgl. Barostim neo™ 
zum Endpunkt 
Sicherheit  
(74 PatientInnen)  
laufende Studien 
Trial zu BAT bei 
Herzinsuffizienz – 
Ergebnisse für  
2021 erwartet 
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Kostenerstattung 
BAT ist derzeit nicht im österreichischen Leistungskatalog enthalten. 
Geschätzte Behandlungskosten für die Implantation liegen bei 3.500 Euro, 
das Barostim neo™-System kostet 21.000 Euro und die Batteriekosten betra-
gen 15.000 Euro, wenn ein Ersatz erforderlich ist [13]. 
 
Fazit 
Die derzeitige Evidenz ist nicht ausreichend, um die Wirksamkeit und Si-
cherheit der BAT nachzuweisen. Obwohl Barostim neo™ das derzeit einzig 
verfügbare BAT-Produkt ist, gibt es für das Produkt bis dato keine Ergebnisse 
kontrollierter Studien, in denen BAT mit einem Scheinverfahren oder BAT 
mit Standardtherapie verglichen wurden. 
Die kleine Studienpopulation ohne Kontrollgruppen, fehlende Verblindun-
gen sowie die wenigen Studien zum Produkt der zweiten Generation tragen zu 
einer insgesamt sehr niedrigen Qualität der Evidenz bei. Alle Studien wurden 
entweder direkt vom Hersteller finanziert oder mehrere AutorInnen erhielten 
Beratungsgebühren. Eine unabhängig durchgeführte Studie konnte nicht iden-
tifiziert werden. Besonders hervorzuheben ist, dass der wichtigste Endpunkt 
(Verringerung der Anzahl an kardiovaskulären Ereignissen im Vergleich zur 
Standardtherapie) in keiner der Studien betrachtet wurde. 
Fehlende Therapieadhärenz stellt eines der Hauptprobleme bei der Blutdruck-
kontrolle dar, wird jedoch in klinischen Studien selten gemessen, und wenn 
dann nur in Form von Fragebögen, anstelle von Urinanalysen oder anderen 
objektiven Messungen. Eine Erhöhung oder Verringerung der Therapieadhä-
renz während der Studien könnte daher zu einer wesentlichen Verzerrung der 
Studienergebnisse beitragen. Zukünftige klinische Studien sollten eine Eva-
luierung der Therapieadhärenz einschließen und die Blutdruckreduktion ba-
sierend auf 24-Studen Blutdruckmessungen beurteilen. Abgesehen von einer 
Blutdrucksenkung, sollten neue Technologien zur Therapie der TRH einen 
Nutzen in Bezug auf eine langfristige Reduzierung der kardiovaskulären Er-
eignisse und damit der Mortalität und Morbidität aufweisen können.  
 
Empfehlung  
Auf Basis der vorliegenden Evidenz wird die Aufnahme in den Leistungska-
talog derzeit nicht empfohlen. Die vorhandene Evidenz zur Wirksamkeit und 
Sicherheit wurde als nicht ausreichend angesehen. Eine Re-Evaluierung wird 
empfohlen, wenn aussagekräftige und kontrollierte Langzeitdaten zur Ver-
fügung stehen, ehestens 2020.  
 
 
bislang keine Erstattung 
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Produkts: 21.000 Euro  
Conclusio: 
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1 Scope 
1.1 PICO question 
Is baroreceptor activation therapy in patients with treatment-resistant hy-
pertension a more effective and safe alternative to decrease blood pressure 
and reduce the number of cardiovascular events in comparison to standard 
therapy with medication? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Patients with treatment-resistant hypertension:  
systolic blood pressure >140mmHG despite drug- therapy with three or more 
antihypertensive medications, including one diuretic agent, in the maximal indicated 
doses and after diagnostic exclusion of secondary hypertension (ICD I15) 
ICD-10 Code: I10 essential (primary) hypertension 
MeSH terms: hypertension (C14.907.489) 
Synonyms: high blood pressure; (atrial) (benign) (essential) (malignant) (primary) 
(systemic) hypertension; treatment-resistant, therapy-resistant, resistant hypertension 
Intervention Baroreceptor activation by implantation of a baroreceptor stimulation device to lower 
blood pressure by stimulating the carotid baroreflex;  
Synonyms: baroreflex activation therapy, baroreceptor stimulation therapy, carotid 
baroreceptor stimulation 
MeSH terms: baroreflex (G09.330.380.057, G11.561.731.063) 
Devices: Barostim neoTM; Rheos® system/ Rheos® device 
Companies: CVRx, Inc. Minneapolis 
Control placebo/ sham procedure (by activating device at different time points);  
guideline-oriented therapy  
Outcomes  
Efficacy  sustained (>1 year) systolic blood pressure reduction by more than 10 mmHg over  
24 hours (critical) 
 decrease in cardiovascular events (death from cardiovascular causes, non-fatal 
myocardial infarction, acute coronary syndrome not resulting in a myocardial infarction, 
non-fatal stroke, non-fatal acute decompensated heart failure) (critical) 
 QoL (Patient-reported QoL (important) 
 Hospitalisation rate (important) 
 reduction of antihypertensive medication to reduce blood pressure to <140 mmHg 
(important) 
Safety  device-related serious adverse events (SAE): stroke, transient ischemic attack, systemic 
embolization, infection, arterial damage, pain, nerve damage, hypotension, hypertensive 
crisis, injury of baroreceptors, cardiac arrhythmias, worsening of kidney disease (critical) 
 procedure related SAE: nerve damage, pain of glossopharyngeal nerve, surgical or 
anaesthetic complications (critical) 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
Baroreceptor activation therapy for treatment-resistant hypertension 
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Study design  
Efficacy Randomised controlled trials (RCT) 
Prospective non-randomised controlled trials (NRCT)  
Before-after studies 
Prospective observational studies: cohort studies, case- control studies (N>20) 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
Prospective case-series, registries (N>20) 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is baroreceptor activation therapy (BAT)? 
A0020 For which indications has BAT received marketing authorisation or CE marking? 
B0002 What is the claimed benefit of BAT in relation to the comparators? 
B0003 What is the phase of development and implementation of BAT and the comparator(s)? 
B0004 Who administers BAT and the comparators and in what context and level of care  
are they provided? 
B0008 What kind of special premises are needed to use BAT? 
B0009 What supplies are needed to use BAT? 
A0021 What is the reimbursement status of BAT? 
 
Health problem and Current Use 
Element ID Research question 
A0002 What is the condition in the scope of this assessment? 
A0003 What are the known risk factors of treatment resistant hypertension (TRH)? 
A0004 What is the natural course of TRH? 
A0005 What is the burden of disease for the patients with TRH? 
A0006 What are the consequences of TRH for the society? 
A0024 How is TRH currently diagnosed according to published guidelines and in practice? 
A0025 How is TRH currently managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is TRH utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of BAT on mortality? 
D0003 What is the effect BAT on the mortality due to causes other than the target disease? 
D0005 How does BAT affect symptoms and findings (severity, frequency) of the disease  
or health condition? 
D0006 How does BAT affect progression (or recurrence) of the disease or health condition? 
D0011 What is the effect of BAT on patients’ body functions? 
D0016 How does the use of BAT affect activities of daily living? 
D0012 What is the effect of BAT on generic health-related quality of life? 
D0013 What is the effect of BAT on disease-specific quality of life? 
D0017 Was the use of BAT worthwhile? 
 
Baroreceptor activation therapy for treatment-resistant hypertension 
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Safety 
Element ID Research question 
C0008 How safe is BAT in comparison to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying BAT? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed by the use of BAT? 
C0007 Is BAT and comparator(s) associated with user-dependent harms? 
 
 
2.2 Sources 
Description of the technology 
 Handsearch in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospitals  
Health problem and Current Use 
 Handsearch in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospitals  
For the domains clinical effectiveness and safety a systematic literature search 
and hand search was conducted, and described in detail in 2.3.  
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on the 06.12.2017  
in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was limited to the years 2008 to 2017, and to articles 
published in English or German. After deduplication, overall 414 citations 
were included. The specific search strategy employed can be found in the Ap-
pendix.  
Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trials registries (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Tri-
als) was conducted on the 03.01.2018 resulting in 31 potential relevant hits. 
Quellen: systematische 
Suche, Handsuche, 
Informationen der 
Hersteller und des 
einreichenden 
Krankenhauses 
systematische 
Literatursuche in  
4 Datenbanken  
Suche nach laufenden 
Studien 
Methods 
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One manufacturer of the most common product (Barostim neo™) submitted 
15 publications, yet these citations were already included in the systematic 
search.  
Two additional publications were found by handsearch.  
 
 
2.4 Flowchart of study selection 
Overall 414 hits were identified. The references were screened by two inde-
pendent researchers (KH, RW) and in case of disagreement, a third researcher 
was involved to solve the differences. The selection process is displayed in 
Figure 2-1. 
 
Figure 2-1: Flowchart of study selection (PRISMA Flow Diagram) 
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(n=7) 
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Within the systematic search, we also identified one systematic review (SR) 
on BAT [14], however, due to methodological limitations of the review and 
conflict of interest, we decided not to include the review as a whole, but ra-
ther compare if the included studies would also meet the inclusion criteria 
for this review. This was not the case; no additional studies were included.  
Furthermore, three health-technology assessments were identified, stemming 
from the UK (NICE) [15], Canada (CADETH) [16], and Australia (Asernip) 
[17]. We compared these reports with our findings, and searched references 
for additional studies and background information on BAT.  
 
 
2.5 Analysis 
We retrieved data from the selected studies and systematically extracted 
those into the data-extraction-tables (see Table A-1 and Table A-2). No fur-
ther data processing (e.g. indirect comparison) was applied.  
Two independent researchers (KH, RW) systematically assessed the quality 
of evidence and risk of bias (RoB) using the Cochrane Risk of Bias tool for 
RCTs [18] and the IHE Risk of Bias checklist for case series [19]. The risk of 
bias analysis for each individual study can be found in the Appendix (Table 
A-3 and Table A-4). 
 
 
2.6 Synthesis 
Due to the heterogeneity of studies, study design, and the paucity of data no 
meta-analysis was calculated. Hence, a qualitative synthesis of efficacy and 
safety data was performed. The questions were answered in plain text format. 
In addition, a GRADE evidence table and a GRADE summary of findings 
table were created in order to synthesize data on each selected outcome cate-
gory across studies (Table A-7and Table A-5).  
 
1 rezenter SR zu BAT, 
jedoch Ausschluss 
aufgrund methodischer 
Mängel 
3 HTAs zu BAT 
Datenextraktion  
aus Studien 
Qualitätsbeurteilung der 
Studien mit Cochrane 
RoB und IHE Checkliste 
qualitative Synthese  
der Evidenz 
Zusammenfassung der 
Ergebnisse mit GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is Baroreceptor Activation Therapy (BAT)  
and its comparators? 
Baroreceptor activation therapy (BAT) is a treatment option proposed for 
patients with treatment-resistant hypertension (TRH).  
Baroreceptors are a mechanosensitive sensory nerve ending in the walls of 
the carotid sinuses and the aortic arch that measure and respond to a rise 
and fall in the arterial BP [20]. As response to increasing BP, the barorecep-
tors send afferent impulses to the central nervous system that reflectively 
decrease sympathetic activity and increase parasympathetic activity, leading 
to a reduction of BP. Conversely, if BP falls the receptors cease their stimu-
lation. This reflex mechanism of the body to respond to high or low BP is 
called carotid baroreflex.  
By inducing the baroreflex, BAT activates the carotid baroreceptors with 
electric impulses. The stimulation leads to a decrease of sympathetic activi-
ty, a relaxation of the blood vessels (vasodilatation), decrease of the heart 
rate and ultimately a reduction of BP [20]. Figure 3-1 shows the anatomic 
location of the baroreceptors and working mechanism behind BAT [2].  
 
Figure 3-1: Baroreceptor activation therapy (A = anatomic location of the baroreceptors at the carotid sinus;  
B = BAT operating-principle; C = BAROSTIM NEO™ device), adapted from [2] 
The stimulation is performed by a neurostimulator device, which consists of 
a pulse generator (left side of picture C) that is connected to a 2mm sized 
electrode (right side of picture C). The implantable pulse generator (IPG) is 
similar to a pacemaker and implanted under the skin below the collarbone. 
The carotid sinus lead connected to the IPG is tunnelled under the skin, and 
the electrode is sutured to the carotid sinus. A wireless programmer system ex-
ists to activate and deactivate the device externally and to customize the stim-
ulation intensity by changing the frequency and the amplitude of the stimu-
lation.  
Einsatz von BAT bei 
therapieresistentem 
Bluthochdruck (TRH) 
 
Barorezeptor-Reflex: 
Barorezeptoren 
aktivieren das zentrale 
Nervensystem bei 
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des Blutdrucks (BD) 
BAT stimuliert mittels 
elektrischen Impulsen 
die Barorezeptoren in 
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hierbei eine BD-Senkung 
Stimulation erfolgt 
mittels Impulsgenerator 
der mit einer 2 mm 
großen Elektrode 
verbunden ist; 
Ein- und Ausschalten 
sowie das Anpassen der 
Stimulationsfrequenz 
erfolgt über ein externes 
Programmiersystem  
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Marketed products and comparators 
The Barostim neo™ by CVRx. Inc is currently the only marketed device that 
activates the baroreceptor reflex by electric impulses.  
However, other procedures and devices similarly target the sympathetic ac-
tivity in order to lower the BP:  
The MobiusHD® by Vascular Dynamics aims at endovascular baroreflex am-
plification by use of a stent-like device that increases wall strain in the carotid 
sinus. The baroreceptors sense the strain as an increase of pressure and re-
spond by inhibiting sympathetic outflow. The procedure provides a passive 
amplification of the baroreflex without the need for electric stimulation, and, 
as the self-expanding device is implanted through the femoral artery by a 
guidewire similarly as a carotid stent, is suggested to be a less invasive pro-
cedure [21]. However, data on efficacy and safety are very limited so far, and 
we only identified one study on this procedure in the systematic search. Sev-
eral CALM studies (Controlling and Lowering Blood Pressure with the Mo-
biusHD®) currently investigate the efficacy and safety profile. The initial first-
in-human open-label study on 30 patients with TRH showed a significant re-
duction in BP at an acceptable safety profile [21], however, these data need 
to be confirmed by controlled studies and RCTs. The CALM-II study, a mul-
ticenter, prospective sham-controlled RCT in Europe and the US was initi-
ated in 2017 (Table A-7).  
Another procedure targeting sympathetic activity, yet in the renal arteries is 
catheter-based radiofrequency ablation of renal sympathetic nerves, also called 
renal denervation (RDN). A recent double-blind RCT, Symplicity HTN 3, 
with 535 participants with TRH could not prove the benefit of this technique 
[22]. A recent sham controlled RCT on 80 patients confirmed the biological 
proof-of principle to lower BP in absence of anti-hypertensive medicines, how-
ever, was not compared to standard treatment, and did not include patient-
relevant outcomes on changes in mortality or morbidity [23]. Following the 
results of the first trial and subsequent studies, a larger ongoing internation-
al trial was halted prematurely [24].  
All of these device-based strategies to lower BP in patients with TRH can be 
regarded as experimental, as substantial evidence proving efficacy and safety 
are lacking to date. Furthermore, none of these techniques is reimbursed and 
included in the Austrian benefit catalogue. Thus, guideline oriented therapy 
(as described in A0025), as well as sham-controlled procedure were chosen 
as comparators to assess effectiveness in this report.  
B0002 – What is the claimed benefit of BAT in relation  
to the comparators? 
The claimed benefit of BAT is the ability to lower BP despite failure of >3 
pharmacological therapies. BAT was described to be the only procedure to 
target both sympathetic and parasympathetic limbs of the autonomic nerv-
ous system [25]. However, it is possible that novel techniques such as the Mo-
biusHD® would also influence parasympathetic activity, as both interventions 
target the baroreceptor reflex. Furthermore, adherence was suggested to be 
improved and potentially lead to a reduction of dosages or anti-hypertensive 
medicines prescribed [25]. Concurrently, heart rate is decreased and benefi-
cial effects in patients with heart failure have been described and are current-
ly investigated.  
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Administration, Investments, personnel and  
tools required to use the technology and the comparator(s) 
B0004 – Who administers BAT and in what context and level  
of care are they provided? 
B0008 – What kind of special premises are needed to use BAT? 
B0009 – What supplies are needed to use BAT? 
Barostim neo™ consists of the IPG, the carotid sinus lead, implant adapter, 
implant tool, and the program system [26].  
The implementation of BAT requires a surgical procedure and takes place in 
a hospital setting. The patient receives general anaesthesia or conscious seda-
tion for the procedure. A surgeon, trained to perform the procedure as well 
as an experienced anaesthetist are needed.  
The surgical procedure consists of three phases: exposure of the carotid sinus, 
carotid sinus mapping and positioning of the electrode and implanting the 
IPG under the skin. In order to identify the optimal location for placing the 
electrode, a mapping of the carotid sinus and system testing is performed dur-
ing the procedure. Subsequently, the electrode is sutured to the vessel, and the 
IPG under the skin near the clavicle. After surgery, patients remain in hos-
pital for approximately three days, if no complications occur (a maximum of 
four days and a minimum of two days) (information provided by submitting 
hospital).  
Prior to surgery, preoperative duplex ultrasonography should confirm the ab-
sence of complex arterial anatomy and verify absence of any stenosis greater 
than 50% of the carotid arteries, as well as the absence of any ulcerative 
plaques [26].  
The device is usually activated one month after the implantation in an am-
bulatory setting.  
 
Regulatory & reimbursement status  
B0003 – What is the phase of development and implementation of BAT? 
The Barostim neo™device is the second generation of baroreceptor stimula-
tors by CVRx. The first clinical trial on the second generation device was 
published in 2012 [7]. The device received market-authorization in Europe 
(CE-mark) for the treatment of resistant hypertension in 2011 and for the 
treatment of reduced ejection heart failure in 2014 (information provided by 
the manufacturer).  
The predecessor device is the Rheos® system, which received CE mark in 
2007. This device is not marked anymore. The first feasibility trial was per-
formed in 2006; a randomised controlled trial (RCT) was completed in 2011. 
The reason for market withdrawal was the end-of-battery life, which was very 
short with one-and-a-half to a maximum of two years [10]. To date, all Rhe-
os® devices have been replaced with the new generation device (information 
provided by manufacturer in personal correspondence). In contrast to the sec-
ond generation, the Rheos® system consisted of two bilateral leads to both the 
left and right carotid sinus and a bigger IGP.  
Barostim neo™ umfasst 
Karotissinuselektrode, 
IPG, 
Programmiersystem 
BAT-Implantation  
als minimal-invasive 
Intervention  
chir. Eingriff mit 
Spitalsaufenthaltsdauer 
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US-Untersuchung  
zur präoperativen 
Diagnostik 
BAT-Aktivierung ca.  
1 Monat nach Eingriff 
Barostim neo™:  
2. BAT-Generation-CE-
Marks zur Behandlung 
von TRH (2011) und 
Herzinsuffizienz (2014) 
kein Einsatz mehr des 
Vorgängermodells 
Rheos® system, 
Austausch aller Geräte, 
Grund: kurze 
Batteriedauer  
(1,5-2 Jahre); Elektroden 
an beiden Halsseiten  
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The Barostim neo™ is fairly different to the first generation, with only one 
stimulating electrode to one carotid sinus. The device has a smaller IGP, can 
be implanted with a smaller surgical incision (<5cm) and is thus less inva-
sive and requires less recovery time, since surgical incision is needed on only 
one side of the neck [27]. Furthermore, the battery life is said to be increased 
to five to six years (information provided by manufacturer in personal corre-
spondence). These changes are claimed to improve the safety profile of the 
second generation device, reduce procedural time and patient discomfort, 
without changes in performance of BP reduction. 
A0020 – For which indications has BAT received marketing  
authorisation or CE marking? 
In addition to resistant hypertension, Barostim neo™ has received CE mark-
ing for the treatment of reduced ejection heart failure in 2014. For the latter 
indication, preliminary evidence exists from two ongoing clinical trials (NCT-
01471860; NCT01720160). Both trials are not completed yet, but initial evi-
dence from a first interim analysis after six months of treatment is available 
[28, 29]. Due to the early stage of evidence development, we deemed an as-
sessment of this second indication premature.  
In the United States, BAT is under clinical evaluation for both indications 
but has not received market-authorisation. FDA granted ‘Humanitarian De-
vice Exemption’ to the participants of the Rheos Pivotal trial that showed sus-
tained BP reduction, allowing CVRx.Inc. to sell the second generation device 
to those patients as replacement of the Rheos® system [30].  
A0021 – What is the reimbursement status of BAT? 
BAT is currently not included in the Austrian benefit catalogue, thus hospi-
tals performing BAT would have to cover treatment costs for their patients.  
A cost-effectiveness analysis for the European healthcare settings in 2014 de-
scribed treatment costs for the implantation with 3,500 Euro [13]. The Barost-
im neo™ system itself costs 21,000 Euro, and the battery costs 15,000 Euro if 
replacement is needed. The replacement procedure for the battery was ap-
proximated with 2,000 Euro. Since no substantial changes in the therapeutic 
approach can be expected, apart from a claimed change in anti-hypertensive 
medications, these costs can be regarded as additional costs to the current 
treatment costs of TRH.  
 
Barostim neo™ 
Elektrode nur bei einem 
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Eingriff weniger invasiv;  
Batteriedauer mit  
5-6 Jahre angenommen 
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laufen, daher verfrüht 
für HTA-Bericht 
in USA laufende 
klinische Evaluation  
zu BAT für beide 
Indikationen 
bislang keine Erstattung 
von BAT in Österreich 
geschätzte Kosten  
des Produkts:  
21,000 Euro  
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0002 – What is the disease or health condition in the scope  
of this assessment?  
The scope of this assessment was treatment-resistant hypertension (TRH). 
Hypertension is as defined as resistant if three antihypertensive medications 
do not achieve control of blood pressure (BP). Patients with persistent hyper-
tension are at high risk to have cardiovascular events (CV) or subsequent re-
nal failure.  
Definition of TRH:  
Resistant hypertension is defined as BP that remains above goal despite ad-
hering to the maximally tolerated doses of three antihypertensive drugs with 
complementary mechanism of action, including one diuretic according to the 
American College of Cardiology (ACC) and American Heart Association 
(AHA) consensus guidelines from 2017 [1]. This recent definition is in line 
with the previous 2013 definition by the European Society of Hypertension 
(ESH) and the European Society of Cardiology (ESC) [4].  
The definition of the goal BP differs in the two guidelines since the 2017 
ACC/AHA guidelines defined a new goal BP as below 130 mmHg systolic and 
80 mmHg diastolic. The ESH/ESC guidelines, among other guidelines, de-
fine goal BP as below 140 mmHg systolic and 90 mmHg diastolic [4]. The 
new ACC/AHA definition of goal BP came as response to the results of the 
SPRINT trial showing significantly reduced mortality rates, and number of 
CV in the intensive treatment group with a BP below 130 mmHg [1, 31]. How-
ever, since certain patient populations were excluded in the study, such as 
diabetics, patients younger than 50 years of age, patients with a prior stroke, 
and those with heart failure, some guidelines, and the Austrian Society for 
Hypertension only recommend the new goal BP for patients with similar char-
acteristics as the SPRINT study population [32, 33].  
Patients with TRH can have both a high systolic and a high diastolic BP, but 
an isolated elevation of the systolic blood pressure (SBP) is common, in par-
ticular in older patients. Isolated systolic TRH is more difficult to manage, 
as often underlying conditions such as stiff aorta make systolic BP control 
harder to achieve, and intensification of therapy may result in too low dias-
tolic BP [34].  
Importantly, resistant hypertension is not synonymous with uncontrolled hy-
pertension. Several other causes of uncontrolled hypertension exist includ-
ing secondary causes for hypertension and pseudo-resistance due to non-
adherence and inadequate treatment regimens (see differential diagnosis). 
A0003 – What are the known risk factors  
for treatment-resistant hypertension (TRH)? 
Predicting patient characteristics and risk factors to develop TRH are a high 
baseline BP (particularly SBP), older age, obesity, African-American race, 
chronic kidney disease (CKD) and diabetes mellitus [34].  
Potentially reversible factors that could cause or contribute to TRH include 
suboptimal therapy, lifestyle and diet, medications that can raise the BP, and 
secondary causes of hypertension [34].  
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A0004 What is the natural course of TRH? 
There is no ultimate cure for hypertension and TRH, and patients need long-
lasting, chronic therapy to lower the BP and concurrently the risk for CV 
events. Age and comorbidities could worsen TRH, especially if BP is not 
controlled by medication or therapy.  
Hypertension, especially if not controlled, is a leading cause of cardiovascular 
and renal diseases and it increases the risk for stroke, coronary artery disease, 
arrhythmias, and heart-, and renal failure. Patients with TRH are character-
ised by an increased prevalence of target organ-damage [35].  
 
Current clinical management of the disease or health condition 
A0024 – How is TRH currently diagnosed  
according to published guidelines and in practice? 
In order to diagnose patients with suspected TRH other causes of uncon-
trolled hypertension need to be ruled out. The following differential diagno-
ses need to be considered [34]:  
 Pseudo-resistant hypertension:  
Patients with pseudo-resistant hypertension have poorly controlled 
hypertension that appears to be resistant but is actually attributable 
to other factors.  
The five most common reasons for pseudo-resistance are:  
 Inaccurate BP measurements (for instance by use of an inadequate 
cuff size) 
 Poor adherence to lifestyle and dietary measures to lower BP 
 Poor adherence to antihypertensive therapy:   
Poor therapy adherence is a major cause of uncontrolled hyperten-
sion. Several studies estimated the percentage of non-adherent hy-
pertonic patients to be between 35-80% [36-38], whereby fewer med-
ications were detected than prescribed in patients urinary or blood 
samples. The highest prevalence of partial and total non-adherence 
was found among patients with inadequate BP control [36, 38]. 
 Suboptimal antihypertensive therapy:  
From the medical side, suboptimal therapy is also a common cause 
of uncontrolled hypertension, due to lacking administration of more 
effective drugs, suboptimal doses, or inadequate combinations of 
antihypertensive medicines [34]. 
 White coat hypertension (‘isolated clinic/office hypertension’) re-
fers to patients who have BP readings above 130/80 mmHg when 
measured in the doctor’s office, but normal BP when measured in 
non-office readings or in 24-hours ambulatory blood pressure meas-
urements (AMBP) [34]. One indicator for white coat hypertension 
is high office BP without signs of target organ damage, and symp-
toms of hypotension, such as fatigue, dizziness, related to overtreat-
ment with antihypertensive medication [35].  
 secondary causes of hypertension:   
Patients with resistant hypertension are more likely to suffer from 
underlying secondary causes for hypertension than the general hyper-
tensive population. In a study on renal denervation for the treatment 
of TRH, almost 50% of the 1,416 patients with TRH needed to be ex-
cluded due to secondary causes of hypertension [39]. The most com-
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mon causes of secondary hypertension include primary aldosteronism, 
renal artery stenosis, CKD, and obstructive sleep apnea. Less common 
causes are pheochromocytoma, Cushing’s syndrome, and aortic coarc-
tation [1, 4, 34]. 
The adequate diagnostic approach for suspected TRH requires detailed in-
formation on the patient’s history, including lifestyle characteristics and diet, 
a detailed physical examination and laboratory test to identify risk factors 
and exclude secondary causes of TRH [4]. Laboratory test should include 
measurement of serum electrolytes, glucose, and creatinine as well as a uri-
nalysis with estimation of proteinuria.  
 
Figure 4-1: Diagnostic evaluation and treatment for resistant hypertension [1] 
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The definition of TRH as BP above 130/80mmHg [1] or 140/90 mmHg [4] de-
spite three or more antihypertensive medicines is based on office BP measures. 
Given the high number of white-coat hypertension in suspected TRH patients, 
24-hours AMBP is recommended as integral part of the diagnosis of TRH [4, 
35]. Furthermore, secondary causes of hypertension need to be considered. 
An absence of the night-time drop of BP (‘dipping’) or increase of BP during 
night (‘reverse dipping’) provide clues for the presence of secondary hyper-
tension and can be seen in the 24-hour AMBP measurements [35]. The diag-
nostic and management algorithm for patients with suspected TRH based on 
the 2017 ACC/AHA guidelines is presented in Figure 4-1.  
A0025 – How TRH currently managed  
according to published guidelines and in practice? 
A combination of non-pharmacologic and pharmacologic approaches is rec-
ommended for the treatment of TRH [4].  
Non-pharmacologic therapy includes the identification and subsequent treat-
ment of potentially reversible and lifestyle related factors that contribute to 
TRH [24]. Initially, medications that raise BP need to be discontinued and 
lifestyle related factors modified. A low-salt diet, weight loss in overweight 
patients and moderation of alcohol intake are essential components of TRH 
treatment. Involving the patient in monitoring their BP at home and increas-
ing awareness of the risk factor may help to improve control of BP.  
The pharmacologic treatment of resistant hypertension involves combinations 
of three or more drugs. The preferred three-drug regimen consists of an an-
giotensin-converting enzyme (ACE) inhibitor or angiotensin receptor block-
er (ARB), a long-acting calcium channel blocker such as amlodipine, and a 
long-acting thiazide diuretic, preferably chlorthalidone [4]. If hypertension 
persists, the ESH/ESC guidelines recommend the use of mineralocorticoid re-
ceptor antagonists such as spironolactone or eplerenone, the alpha-1-blocker 
doxazosin and a further increase of diuretic doses. If renal function is im-
paired, the switch to a loop diuretic replacing thiazides or chlorthalidone is 
suggested. Monitoring of serum potassium levels for both hypokalemia and 
hyperkalemia are necessary if are mineralocorticoids used [4, 24]. 
As described above, secondary causes need to be considered. If a secondary 
cause is suspected or if BP remains high despite six months of treatment in-
tensification, referral to a hypertension specialist is recommended [24].  
If multiple-drug treatment at the maximum tolerated dosage remains ineffec-
tive, the ESH/ESC 2013 guidelines suggest taking other invasive approaches 
such as BAT into consideration (class IIb, Level C1). While the utility of re-
nal denervation has not been established in a large, blinded RCT (Symplicity-
HTN-3), the results for BAT are still pending. It is recommended that these 
experimental procedures remain in the hands of experienced specialists and 
are restricted to hypertension centres. Furthermore, the recommendation is 
limited to patients at high risk, with >160 mmHg SBP or >110 mmHg DBP 
and where actual resistance has been confirmed by ABPM [4].  
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Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with TRH? 
A0006 – What are the consequences of TRH for the society? 
As with hypertension, TRH is usually asymptomatic. The patients would 
therefore often not realize having an elevated BP, and would not complain 
about symptoms.  
The chronicity of the condition and the significance as a risk factor for CV 
events makes most of the burden for patients, and society. Due to the lack of 
symptoms, compliance and adherence to the antihypertensive medicines is a 
major factor when treating hypertension and TRH.  
Since hypertension is a major risk factor for CV, the societal burden comes 
with the number of CV and/or renal events, and related treatment costs.  
 
Target population 
A0007 – What is the target population in this assessment? 
A0023 – How many people belong to the target population?  
A0011 – How much are the technologies utilised? 
The target population of this assessment are patients diagnosed with TRH as 
defined above, after exclusion of secondary causes of uncontrolled hyperten-
sion and pseudo-resistance.  
BAT is contraindicated in patients with baroreflex failure or autonomic neu-
ropathy, uncontrolled, symptomatic bradyarrhythmias, carotid atherosclero-
sis greater than 50% or ulcerative plaques in the carotid artery [26]. 
The actual prevalence of TRH is not known and controversially discussed. A 
wide variability exists in the reported prevalence ranging from 2% to 30% of 
hypertensive patients [3], depending on the population examined [4].  
Using population-based data from the National Health and Nutrition Exam-
ination Survey from 2003 to 2008 in the US Persell et al. reported a preva-
lence of 8.9% among individuals with hypertension (defined as a BP ≥140 
mmHg systolic or ≥90 mmHg diastolic), and 12.8 % among patients treated 
with antihypertensive medication [40]. A Spanish patient register of 68,000 
patients showed a similar prevalence of 12.2%; however, after AMBP, one 
third of these patients were diagnosed as having white-coat resistance [41]. 
The prevalence and incidence rate was substantially lower in a retrospective 
analysis in two US states by Daugherty et., showing that among 205,750 pa-
tients with newly diagnosed hypertension, 1.9% developed TRH with a me-
dian of 1.5 years from initial treatment start [3].  
According to an analysis by Egan et al. the number of TRH patients is likely 
to rise in the coming years [42]. They showed a difference in prevalence rates 
of 15.9% in 1998-2004 and 28% in 2005-2008 (data was derived from the Na-
tional Health and Nutrition Examination Survey and included 13,375 pa-
tients). An increased awareness and improved screening could, however, also 
explain the rise in the numbers of TRH patients.  
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One reason for the wide range in prevalence rate is that not all patients with 
uncontrolled hypertension would meet the defined requirements for TRH, 
and poor adherence or inadequate treatment regimens are often the underly-
ing factors for uncontrolled hypertension. Furthermore, not all epidemiologic 
studies include detailed information on medication dosing and treatment ad-
herence [43]. An evaluation of the prevalence of truly resistant hypertension 
among 140 patients with uncontrolled hypertension showed that only 45% 
would meet the definition of TRH [44]. Moreover, an estimated 37-44% of 
patients with uncontrolled hypertension have white-coat hypertension [41].  
In 2015, the prevalence of hypertension in Austria was estimated at 25.2 % 
among men and 16.8% among women [45]. In a recent Austrian cross-sec-
tional multicentre study on 4303 patients with hypertension, only 40% of pa-
tients achieved BP control (defined as <140/90 mmHg office BP), despite a 
high degree of awareness (93% of study participants answered to be aware of 
the condition and associated risk factors) [46]. The number of patients with 
true TRH in Austria is not known. 
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 decrease in cardiovascular events (CV) (death or morbidity from car-
diovascular causes: non-fatal myocardial infarction, acute coronary syn-
drome, non-fatal stroke, non-fatal acute decompensated heart failure) 
(critical) 
 decrease in mortality due to CV events compared  
to standard therapy 
 decrease in morbidity due to CV events compared  
to standard therapy 
 sustained BP (>1 year) reduction by more than 10 mmHg, measured 
by 24 hours AMBP (critical). While BP reduction is usually regarded 
as surrogate parameter, we deemed it crucial to assess the effectiveness 
of BAT, as the primary goal of this therapy is BP reduction.  
Furthermore, the following outcomes were considered relevant  
to answer the research questions:  
 Hospitalisation rate  
 reduction of antihypertensive medication (number of anti-hypertensive 
medicines) to reduce BP to <140 mmHg  
 Quality of life (QoL) 
 
 
5.2 Included studies 
In total, seven references to six studies were selected for data extraction, of 
which one was a randomised controlled trial, one a randomised cross-over 
trial, and five studies were case series, of which one was the long-term fol-
low-up of an included study. The case series did not include a comparison 
group, yet, had a before-after design, comparing baseline values with results 
after at least 6 months of BAT therapy. Due to the limited amount of availa-
ble evidence, case studies with a minimum number of 20 cases and a pro-
spective, before-after design were thus also considered to also answer effica-
cy-related research questions.  
Other than the follow-up study on long-term BAT effects, we did not include 
studies where duplication of data was suspected, due to similar sampling pe-
riods, study centres, and patient characteristics. Furthermore, we excluded 
conference abstracts and posters.  
All studies were either sponsored by the device manufacturer or several au-
thors received consultancy fees from the manufacturer.  
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Rheos® system 
Three studies assessed effectiveness and safety of the first generation devices, 
the Rheos® system, which is not marketed anymore, and where devices have 
been entirely replaced with the second generation device, the Barostim neo™. 
For completeness, we extracted these data and describe them in the results 
questions were relevant, however, did not consider them for the GRADE sum-
mary of findings and the subsequent recommendation, as this product is not 
available anymore.  
The three studies on the Rheos® system were one RCT, and two case series, 
of which one was the long-term follow up of patients included in the Rheos 
trials (DEBut-HT, Rheos pivotal trial, Rheos feasibility study). The two orig-
inal studies included a total of 310 patients, 265 within the Rheos trial and 
45 within the case series. The follow-up study analysed data from 383 patients, 
of which 143 completed 5-year follow-up and 48 completed 6-year follow-up. 
Data from these patients were also included in the two original trials. The 
studies were similar as regard to inclusion and exclusion criteria, mean age 
(53 years), number of anti-hypertensive medicines (on average 5), and per-
centage of female participants (around 40%). The studies had a follow up of 
one year (RCT), two years (case-series), and the follow-up study 6 years.  
Barostim neo™ 
We identified four studies on the Barostim neo™, of which none had a control 
group that did not receive the intervention.  
One study had a randomised, controlled cross-over study-design, whereby both 
groups had received the intervention BAT with the Barostim neo™ one year 
prior to the study, and withdrawal of BAT therapy was assessed [8]. The study 
randomised 16 patients that had previously received BAT with the Barostim 
neo™ for the duration of one year into a BAT-on and a BAT-off group. After 
four weeks, the groups switched from the off-phase to an on-phase and vice 
versa. Patients included in Beige et al. were previously also included in the 
case series by Hoppe et al. 2011 and Wallbach et al. 2016 [5, 7].  
The three remaining case series on the second generation device included a 
total of 106 patients, ranging from 30 to 51 participants [5-7]. The inclusion 
and exclusion criteria were similarly in between studies. The mean age of the 
patients receiving BAT with Barostim neo™ was slightly higher than for the 
trials on the Rheos® system, with a mean age of about 57 years. The mean anti-
hypertensive medicines at baseline were also higher than in the Rheos® study 
population with an average of 6 medicines. Three studies reported an aver-
age BMI above 30, one study did not report on this patient characteristic [5].  
In each of the four studies on Barostim neo™ at least 20% of study partici-
pants had a history of renal denervation (in total 33 of 122). Relevant comor-
bidities of the study population were diabetes (30% of study participants) and 
CKD > stage III (28%); but the proportion of these comorbidities was simi-
lar across studies. One study did not report on these patient characteristics [8].  
All studies on the Barostim neo™ had a follow-up of 6 months, apart from the 
withdrawal study by Beige et al. 2017, which followed patients for eight weeks 
only.  
Table 5-1 provides an overview of the included studies regarding the device, 
the study design, number of participants and lengths of follow-up. Detailed 
study characteristics and results of included studies are displayed in the 
Appendix Table A-1 and Table A-2 and in the evidence profile in Table A-6. 
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Table 5-1: Overview of included studies on Baroreceptor Activation Therapy 
Study 
Bisognano, 
2011 
Scheffers, 
2010 
de Leeuw, 
2017 
Hoppe,  
2012 
Wallbach, 
2015 
Wallbach, 
2016 
Beige,  
2017 
Devices Rheos® 
system 
Rheos® 
system 
Rheos® 
system 
Barostim 
neo™ 
Barostim 
neo™ 
Barostim 
neo™ 
Barostim 
neo™ 
Design RCT Prospective 
case series 
Open-label 
follow-up 
Prospective 
case series 
Prospective 
case series 
Prospective 
case series 
Cross-over 
study 
Number of participants 265 54 383* 30 25 51 16** 
Lengths of follow-up 1 yr 2 yrs 6 yrs 6 months 6 months 6 months 6 months 
Conflict of interest authors received consultancy fee and research grants form CVRx 
* patients were also included in Bisognano, 2011 and Scheffers, 2010 
** patients were also included in Hoppe et al, 2011; Wallbach et al. 2016 
 
 
5.3 Results 
Mortality 
D0001 – What is the expected beneficial effect of BAT on mortality? 
D0003 – What is the effect of BAT on the mortality  
due to causes other than TRH? 
Whether BAT has a beneficial effect on mortality has not been established in 
the studies.  
The RCT on the Rheos® system reported a total number of 7 deaths in the 
whole patient population, of which 4 occurred during the initial 12 months 
follow-up, and additional three in long-term follow-up [12]. The causes of 
death were three intracerebral haemorrhages, two cardio-pulmonary arrests 
and one ruptured aortic aneurysm, and one drug overdose. In the long-term 
follow up on the Rheos® system, de Leeuw et al reported 28 deaths over a time 
span of six years. Whether some of these deaths were related to the therapy, 
or whether on the contrary BAT prevented further deaths as a result of long-
term hypertension, cannot be evaluated, due to a lacking control group of 
TRH-patients that did not receive the intervention. 
In the four studies on the Barostim neo™, no cases of death related to hyper-
tension or the device occurred [5-8].  
 
Morbidity 
D0005 – How does BAT affect symptoms and findings  
(severity, frequency) of TRH? 
Reduction in the number of cardiovascular events 
No studies assessed a difference in the number of CV events between TRH 
patients that received BAT, and patients with conventional standard therapy.  
Reduction of blood pressure 
24-hours ambulatory blood pressure 
In total, three of seven studies reported data on 24-hours AMBP: two obser-
vational before-after case series, and one interventional, randomised cross-over 
withdrawal study.  
keine Ergebnisse zu 
positiven Effekten von 
BAT auf Mortalität 
 
RCT zu Rheos® System 
berichtet 7 Todesfälle – 
davon 4 innerhalb des 
ersten 12 Monate 
follow-ups 
 
im Langzeit follow-up 
28 Todesfälle über  
6 Jahre  
keine Todesfälle in den  
4 Barostim neo™ 
Studien 
keine Studie berichtet 
kardiovaskuläre 
Ereignisse  
3 von 7 Studien 
berichten zu 24-Std.  
BD-Werten  
Baroreceptor activation therapy for treatment-resistant hypertension 
32 LBI-HTA | 2018 
For the first generation device, the case series by Scheffers et al., 2010 pre-
sented data from 15 patients at 12 months of BAT. They reported a signifi-
cant change in systolic AMBP by -13 mmHg (SD ±3), and diastolic AMBP 
by -8 (SD ±2) (n=15; p <0.001) [11]. 
For the second generation device, the case series by Wallbach et al. 2016 re-
ported data form 44 patients at 6 months of BAT. SBP changed by 8 mmHg 
(from 148 mmHg ±17 to 140 mmHg ±23, p <0.01), and DBP by 5 mmHg 
(from 82 ±13 to 77 ±15 mmHg, p> 0.01). In 24 of 44 patients (55%) AMBP 
dropped by more than 5 mmHg.  
Beige et al. 2017 reported changes in AMBP in a randomised cross-over with-
drawal study [8]. They randomised a total of 16 patients that had previously 
received BAT with the Barostim neo™ for the duration of one year into a BAT-
on and a BAT-off group. After four weeks, the groups switched from the off-
phase to an on-phase and vice versa. They hypothesised an increase in BP in 
the BAT-off groups that was similar to the initial BP drop when the device 
was first implanted, and subsequently, a BP drop when BAT is re-activated. 
A significant increase of AMBP by 10 mmHg systolic and 8 mmHg diastolic 
(±4/±3, p=0.007/0.002) during the BAT-off phase compared to the BAT-on 
phase was found. However, the BP change did not reach a similar magnitude 
to the initial BP drop after implantation of the device.  
Office blood pressure  
One comparative study provided data on changes in office BP: the RCT Rheos 
pivotal trial (n=265) [12]. Participants were randomised at a 2:1 ratio, where-
by group A (n=181) received immediate activation of the Rheos® device, while 
group B (n=84) received delayed activation after 6 months. Mean change in 
systolic BP at 6 months was not significantly different between the interven-
tion group and the control group (16 ± 29 mmHg to 9 ±29mmHg; p=0.08). 
For the second generation device, mean changes in office BP were available 
from two case series (n=44, n=30), at 6 months follow-up, but no compara-
tive studies were available. The mean change in systolic BP ranged from – 20 
± 8 to -26 ± 4 mmHg [5, 7].  
The crossover withdrawal study by Beige et al. 2017 reported an increase of 
BP by 10 mmHg after a four-week period of deactivating BAT therapy; how-
ever, it did not reach the same magnitude as the initial BP drop at time of 
implantation.  
Percentage of patients < 140 mmHg  
This outcome was reported by two studies: 
 In the Rheos pivotal trial 42% of patients from the intervention group 
and 24% of patients from the control group achieved a BP reduction 
to < 140 mmHg after 6 months (p=0.005). After one year, when BAT 
was activated in both groups, this number increased to 50% of all pa-
tients [9].  
 Data for the second generation device was available from one case se-
ries by Hoppe et al. 2011 (n=30), showing that 43% of patients achieved 
a BP reduction below 140 mmHg at 6 months of BAT [7].  
1 Fallserie zu Rheos® 
system verzeichnete 
BD-Senkung bei Fallzahl 
von 15 PatientInnen 
1 Fallserie zu Barostim 
neo™ verzeichnete  
BD-Senkung – Sample 
44 PatientInnen bei  
6 Monate follow-up 
1 randomisierte  
Cross-over Studie zu 
Barostim neo™ – Sample 
16 PatientInnen;  
 
erhöhte 24-h BD-Werte 
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Office-messungen: 
nach 6 Monaten  
keine signifikanten 
Gruppenunterschiede 
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Follow-up Daten zu je  
6 Monaten 
BD-Anstieg in Cross-over 
Studie nach 4 Wochen 
2 von 7 Studien berichten 
zu PatientInnen (in %) 
mit BD-Werten  
< 140 mmHg 
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Antihypertensive medication 
The RCT on the Rheos® system did not report on changes in the number of 
antihypertensive medicines.  
In two case-series on the second generation device, no significant changes in 
the number of prescribed antihypertensive medicines were found [6, 7]. Wall-
bach et al. 2016 found a reduction from 6.5 (±1.5) to 6.0 (±1.8) medicines 
(n=51, p=0.03) [5].  
Hospitalisation rate 
There was no data available for this outcome.  
D0006 – How does BAT affect progression (or recurrence) of TRH? 
Long-term open-label follow-up on data of the first generation device showed 
sustained response of BAT at 5 years follow-up with a mean reduction of SBP 
by 30 mmHg and DBP 10 mmHg (n=143; no confidence intervals or stand-
ard deviations were reported) [10].  
There was no comparative data on patients that received standard therapy. 
There was no data available that compared disease progression in terms of 
occurrence of CV events.  
 
Function 
D0011 – What is the effect of BAT on patients’ body functions? 
Apart from a reduction of BP, which is described in D005, BAT is currently 
evaluated for its effects on heart failure.  
The studies did not report on further effects on patients body function.  
D0016 – How does the use of BAT affect activities of daily living? 
None of the identified studies addressed this question.  
 
Health-related quality of life 
D0012 – What is the effect of BAT on generic health-related quality of life? 
D0013 – What is the effect of BAT on disease-specific quality of life? 
No evidence was found on health or disease-specific quality of life.  
 
Patient satisfaction 
D0017 – Was the use of BAT worthwhile? 
No evidence was found on patient satisfaction with BAT.  
 
Veränderungen  
von BD-senkender 
Medikation im RCT  
zu Rheos® system 
unbekannt; 2 Fallserien 
zu Barostim neo™ zeigen 
keine Veränderungen  
keine Angaben verfügbar 
Effektkontinuität  
bei Rheos® system 
vorhanden  
keine Vergleichsdaten 
zu Standardtherapie 
laufende Evaluierung zu 
BAT bei Herzinsuffizienz 
keine Angaben bzgl. 
Einfluss von BAT auf 
Alltagsleben verfügbar 
keine Angaben zu  
LQ verfügbar 
keine Angaben zu 
PatientInnenzufriedenheit 
verfügbar 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Serious procedure-related adverse events (AE): defined as adverse events 
that occurred within the first 30 days of implantation, such as surgi-
cal complications, nerve injury, wound complications, pain of glosso-
pharyngeal nerve, surgical or anaesthetic complications. 
 Serious adverse events (SAE): defined as events that occurred after the 
initial 30 days until the final follow-up. Hypertension or device-related 
AE were considered, as the causality and differentiation are not plau-
sible for most events (i.e sudden bradycardia could stem from a high 
stimulation with BAT, be related to the disease or underlying comor-
bidities, or to drug treatment). The system reference guide provides a 
list of possible adverse events during BAT, such as myocardial infarc-
tion, stroke, transient ischemic attack, systemic embolization, infec-
tion, arterial damage, pain, nerve damage, hypotension, hypertensive 
crisis, injury of baroreceptors, cardiac arrhythmias, worsening of kid-
ney disease, the dislocation or the pulse generator or other reasons re-
sulting in the need for re-operation.  
In accordance with the European Commission guidelines for medical devices 
on SAE reporting, the following definition was applied2:  
SAE is an adverse event that led  
1. to death,  
2. to a serious deterioration in health of the subject that either resulted 
in a life-threatening illness or injury,  
3. a permanent impairment of a body structure or a body function,  
4. in-patient hospitalisation or prolongation of existing hospitalisation,  
5. medical or surgical intervention to prevent life-threatening illness  
or injury. 
 
 
6.2 Included Studies 
To evaluate safety of BAT, no additional studies were identified that met the 
inclusion criteria. Included studies and characteristics are described in 5.2. 
Study characteristics and results of included studies are displayed in Table 
A-1 and Table A-2 and in the evidence profile in Table A-6. 
 
 
                                                             
2 http://ec.europa.eu/consumers/sectors/medical-devices/files/meddev/2_7_3_en.pdf 
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6.3 Results 
Patient safety 
C0008 – How safe is BAT in comparison to standard therapy? 
No studies comparing BAT to standard therapy were available.  
The only comparative data to evaluate safety was derived from the RCT on 
the first generation device, the Rheos pivotal trial [12]. Bisognano et al. 2011 
reported 68 procedural complications, of which 13 patients experienced sur-
gical complications, 13 had nerve injuries with residual effect, 12 patients had 
temporary nerve injuries, seven patients had respiratory complications and 
seven patients wound complications. Furthermore, they reported 34 device-
related adverse events, of which six were hypertension-related strokes, reasons 
for the remaining 28 adverse events were not provided. The Rheos pivotal tri-
al missed its primary safety outcome on procedural safety, targeting an event-
free rate of more than 82%, as only 74.8% of patients were event-free, and 
25% experienced adverse events. For device safety, 87.2% of patients were 
event-free, which exceeded the target criterion of >72%. Five of the 265 pa-
tients had their device removed during the 12 months follow up time.  
Within the six years follow-up, de Leeuw et al. 2017 reported 335 SAEs oc-
curring in 111 patients. 26 SAEs (23%) were directly related to the procedure 
or BAT system. Five SAE were related to the IPG and four events to the ca-
rotid sinus lead, such as migration of the device or lead, tension, and haema-
toma. 12 patients experienced a total of 13 CV events, six hypertensive crises, 
five cases of hypotension, one case of bradycardia. One patient suffered a hy-
pertension-related stroke with residual effects, other complications resolved 
without residual effects.  
For the second generation device, safety outcomes were reported by two case-
series for a total patient population of 74 patients. Hoppe et al. 2012 (n=30) 
described three procedural AE, all of which were resolved: device pocket hae-
matoma, pain near the device site, and wound healing complication. Further-
more, one patient reported pain near the device system beyond 30 days. Wall-
bach et al. 2016 (n=44) described 20 procedure-related AEs and three SAEs. 
The reported procedure-related adverse events were surgical complications, 
wound healing problems, postoperative haematomas, and pain near the sur-
gical wound. Wallbach et al. 2016 reported two cases were revision of surgery 
was necessary, one due to movement of the IPG and one due to wound healing 
defects. Furthermore, one patient experienced a hypertension-related stroke.  
Within the 6 months follow-up, none of the second generation devices need-
ed to be explanted. A detailed listing of adverse events is provided in Table 
A-2.  
C0002 – Are the harms related to dosage or frequency of applying BAT? 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
None of the studies that met the inclusion criteria described harms related to 
dosage or frequency.  
keine Vergleiche bzgl. 
Sicherheit BAT mit 
Standardtherapie 
vorhanden 
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C0005 – What are the susceptible patient groups  
that are more likely to be harmed by the use of BAT? 
No evidence was found in susceptible patients groups more likely to be harmed 
by BAT.  
C0007 – Is BAT associated with user-dependent harms? 
The implantation requires surgical skills, and experience to place the elec-
trode in the correct place. As afore-described, 23 SAE were related to surgical 
and procedural complications. Furthermore, the frequency and amplitude of 
BAT stimulation need to be set correctly by trained personnel in order to en-
sure adequate stimulation that does not result in hypotension, bradycardia or 
other adverse events.  
 
keine Angaben bzgl. 
speziell gefährdeter 
PatientInnen  
BAT-Implantation 
erfordert chir. 
Kompetenz und 
Erfahrung, ebenso 
ExpertInnen für  
BAT-Betrieb und -Ablauf 
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7 Quality of evidence 
RoB for individual studies was assessed with the IHE checklist (case series) 
[47] and with the Cochrane RoB tool for RCTs [18]. Results of the RoB as-
sessment are presented in Table A-3 and Table A-4.  
Regarding the two controlled studies, one was graded with high RoB, due to 
lacking statistical reporting of relevant comparators, a short follow-up and 
partial reporting of patient characteristics. Two of the five case series were as-
sessed with high RoB, due to partial or none reporting of AE, and loss to fol-
low-up. The remaining three studies were considered to have low RoB. 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) scheme for each end-
point individually [48]. Each study was rated by two independent research-
ers. In case of disagreement, a third researcher was involved to solve the dif-
ference. A more detailed list of criteria applied can be found in the recom-
mendations of the GRADE Working Group.  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that of 
the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings table below and in the evidence profile 
in Appendix Table A-6. 
Overall, the strength of evidence for the effectiveness and safety of BAT is 
very low. For the comparison of BAT to standard therapy, no evidence was 
available.  
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Table 7-1: Summary of findings table of BAT 
Outcomes 
Anticipated absolute effects* (95% CI) Relative 
effect 
(95% CI) 
№ of participants  
(studies) 
Certainty of  
the evidence 
(GRADE) 
Comments Risk with standard 
therapy (or BAT-off) 
Risk with Barostim Activation 
Therapy 
Reduction of systolic  
24-hour AMBP 
(Reduction of AMBP )  
 The mean reduction of systolic 
24-hour AMBP in the 
intervention group was 8 mmHg 
lower (2 lower to 14 lower) 
- 44 
(1 observational 
study) 
⨁◯◯◯ 
VERY LOW a,b 
No comparison group was available. 
Reduction of office SBP   The mean reduction of office 
SBP in the intervention group 
was 23 mmHg lower (0 to 0 ) 
- 74 
(2 observational 
studies) 
⨁◯◯◯ 
VERY LOW a,b 
No comparison group was available. 
Confidence Intervals were not reported 
Mortality  
(reduction in the number 
of lethal CV events) 
not reported - - - - The number of lethal CV events in 
comparison to standard management was 
not reported by any of the studies 
Morbidity  
(reduction in the number 
of CV events) 
not reported - - - - The number of CV events in comparison  
to standard management was not reported 
by any of the studies 
Procedure-related 
serious adverse events  
24 events in 74 patients 
 
74 
(2 observational 
studies) 
⨁◯◯◯ 
VERY LOW a,b 
Safety outcomes were only considered  
for the second generation device 
Device-related serious 
adverse events  
4 events in 74 patients 
 
74 
(2 observational 
studies) 
⨁◯◯◯ 
VERY LOW a,b 
Safety outcomes were only considered  
for the second generation device 
a not blinded, no adjusted for confounding  
b small sample size, wide confidence intervals  
c First generation device, different operating mechanism and safety profile; not in clinical use anymore 
Abbreviations: AMBP = ambulatory blood pressure, CI = confidence interval, CV = cardio-vascular, SBP = systolic blood pressure 
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8 Discussion 
The stimulation of the baroreceptors to provoke a decrease in blood pressure 
(BP) fostered new interest in and high hopes for the treatment of resistant 
hypertension (TRH). However, substantial evidence proving the efficacy and 
safety of BAT remains limited. While BAT devices have been introduced to 
the European market already in 2007 when the Rheos® system (the first gen-
eration device) received its CE mark, the available evidence is scarce and the 
quality of evidence is very low.  
For the purpose of this review, we identified seven studies on BAT that met 
our predefined inclusion criteria (Table 1-1): Three studies on the first gen-
eration device, the Rheos® system, and four studies on the second generation 
device, the Barostim neo™. The two generations of devices are fairly different: 
the Barostim neo™ features a smaller electrode requiring a smaller incision, 
and a smaller pulse generator with a longer battery life. Since the electrode is 
placed unilaterally on only one carotid sinus, the surgical procedure is simpler 
and shorter, requiring less recovery time [20]. Due to these substantial mod-
ifications and differences between the two generations of devices, the availa-
ble evidence for each device needed to be evaluated separately, and a pooling 
of efficacy and safety data would not be sensible. Importantly, the Rheos® sys-
tem is not available on the market anymore, and implanted devices have been 
entirely replaced with the second generation device at the end of battery life. 
For the Rheos® system, we could identify one double-blind RCT on 265 pa-
tients [9], one uncontrolled trial on 45 patients (not blinded, not randomised) 
[11], and one open-label follow-up pooling patients from these trials in a six-
year follow-up [10]. The Rheos Pivotal trial was the only controlled study that 
compared active BAT to non-active BAT (sham). However, the controlled pe-
riod was short with only six months, thereafter the devices in the control 
group were turned on and the study continued as an open-label follow-up. For 
the primary endpoint of an SBP reduction by more than 10 mmHg after six 
months no significant difference was observed within the two groups (54% 
in the interventional group, to 46% in the sham group, p> 0.005, office BP). 
In the long-term open-label follow-up of the Rheos® patients, a sustained BP 
reduction in office BP by 35/18 mmHg was documented, and apparently, no 
signs of the formerly expected adaptation of the reflex were noted [10].  
For the second generation device, no controlled studies are available to date 
that compared BAT to sham procedure or BAT to standard management (in-
formation confirmed by manufacturers). We identified three case series with 
a patient population ranging from 33 to 51 patients, and one randomised-
controlled cross-over withdrawal trial on 16 patients [8]. The latter assessed 
whether a withdrawal of therapy in terms of a deactivation of already implant-
ed BAT devices would lead to a substantial increase of BP, comparable to the 
initial BP drop at the time of implantation [8]. To note, patients included in 
this trial were also included in the case series. While Beige et al. 2017 could 
indeed show a BP increase both in AMBP and office BP during the BAT-off 
phases, the increase did not show the same magnitude as the initial BP drop 
at the time of implantation, and thus, the primary endpoint was missed [8]. 
These findings open questions whether the initial BP drop might be related 
to the surgical intervention itself, or if other underlying reasons exists that 
would explain the more pronounced decrease in BP at the time of implanta-
tion. Due to the small case count of only 16 patients, no conclusive evidence 
could be derived from this trial.  
Stimulation der 
Barorezeptoren bei  
TRH durch BAT – jedoch 
eingeschränkte 
Evidenzlage  
7 Studien eingeschlossen; 
3 von 7 Studien zu 
Rheos® system (Gerät 
erster Generation) und 
4 von 7 zu Barostim neo™ 
(aktuell verwendetes 
Gerät);  
getrennte 
Studienbewertungen; 
Geräteunterschiede 
bzgl. Implantation, 
techn. Ausstattung  
und Batterielaufzeit 
1 RCT, 2 Fallserien  
zu Rheos® system; 
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BD-Senkung in 
unkontrollierter Studie 
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keine kontrollierten 
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The evidence from three observational case series reported an average office 
SBP decrease ranging from -20 to -26 mmHg. The observed BP reductions are 
of comparable magnitude to those reported in the Rheos trial [12]. Important-
ly, only one study measured a decrease of BP by means of AMBP, while the 
other studies applied in office BP measurements. The reported decrease in 
AMBP was, however, relatively modest, with an average decrease in SBP by 
8 mmHg. A reduction of at least 5 mmHg was not achieved in 20 of 44 pa-
tients (45%) [5].  
Several guidelines on TRH have recommended the use of AMBP measure-
ments rather than office BP measurements, since the latter is less reproduci-
ble and relate to a greater extent on the situational evoking of BP elevation, 
for instance, due to white coat hypertension [1, 4, 49]. Studies indicated that 
AMBP provides a better prognostic value compared to office BP [50]. Fur-
thermore, office BP measurements are more prone to mistakes in the meas-
urement technique, such as improper patient positioning, wrong cuff size, 
poor timing of measurements, and equipment-related errors [43]. Yet, for the 
whole body of evidence on BAT only two studies reported changes of BP by 
means of AMBP measurements, one on the first (n=45) and one on the sec-
ond generation device (n=44) [5, 11].  
BAT was suggested to reduce the number of needed anti-hypertensive medi-
cations. However, the evidence of a change in the number of anti-hyperten-
sive medications was very heterogeneous without a clear pattern of an increase 
or a decrease.  
Regarding the safety of BAT, comparative evidence was only available from 
the Rheos pivotal trial for the initial 6 months [9]. The implantation of the 
first generation device was associated with a number of SAE, whereby nearly 
5% of patients experience nerve injuries with residual effects. The Rheos 
pivotal trial missed its primary safety endpoint on procedural safety, as one-
fourth of the patients experienced AE related to the surgical procedure. In the 
long-term follow-up de Leeuw et al.2017 reported 335 SAE occurring in 111 
patients [10]. Patients needed to undergo surgical revision and battery re-
placement after one and a half to two years of treatment. Consequently, every 
patient that remained on treatment for more than two years needed to under-
go battery replacement. Apart from the discomfort for the patients to under-
go surgical revision, the battery exchange also comes with large expenses: A 
cost-effectiveness study from the European context documented battery costs 
at 15,000 Euro; procedural costs for the replacement were approximated with 
2,056 Euro [13]. 
In contrast to the first generation device, less procedure-related AE and SAE 
were reported for the second generation. The most commonly reported AEs 
for the Barostim neo™ device were temporary nerve injuries, wound healing 
complications, haematoma, and pain at the site of the device. Regarding SAE, 
Wallbach et al. 2016 reported one case of hypertension-related stroke [5]. 
Since the total patient population on the second generation device is much 
smaller than for the first generation and comparative evidence is missing, true 
differences can only be established by larger, controlled and ideally blinded 
studies. While the safety of the device is claimed to be markedly improved 
in the new generation device, these claims need to be substantiated by con-
trolled studies to prove an actual safety benefit in comparison to standard 
therapy and sham procedure.  
nur 1 von 3 Studien  
zu Barostim neo™ mit  
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BD-Senkung feststellbar 
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The small patient population, lacking control groups and blinding, and the 
paucity of studies on the second generation device contribute to an overall 
very low quality of evidence, both for efficacy and safety-related outcomes. 
Although it is currently the only marked product, no comparative evidence 
on the second generation device is available. All of the studies were either di-
rectly funded by the manufacturer, or first authors received study grants or 
consultancy fees. No independently conducted study could be identified. Re-
porting of safety outcomes was not consistent, and at time lacked details on 
the adverse events. Importantly, the most crucial outcome of a reduction in 
the number of cardiovascular events as compared to standard therapy was 
not assessed by any of the studies. This lack of reporting on this crucial out-
come and the lacking comparison to standard management is also the major 
factor limiting the applicability of the results to the clinical context. Details 
on the applicability of the body of evidence can be found in Table A-6.  
Looking at other emerging technologies for the treatment of TRH, another 
intervention also targeting sympathetic activity is renal denervation, which 
similarly to BAT held great promises and received vast attention in recent 
years [27]. However, through the publication of the first RCT results on renal 
denervation the limited benefit for patients became evident [22]. Similarly, 
the Rheos Pivotal Trial as first RCT on BAT failed to establish clear benefits 
on efficacy and safety, as it missed two out of five primary outcomes. On ba-
sis of these mixed results, the FDA did not approve the device to treat TRH, 
but only allowed an open-label extension study under an investigational de-
vice exemption. Under this exemption, the new generation device is current-
ly evaluated within the Barostim neo™Pivotal Trial. Results were initially 
planned to be published by 2015 and later postponed to September 2017; yet 
to date, the results of this trial are still pending.  
Another emerging technology targeting the baroreceptors and the barorecep-
tor reflex is a stent-like device, the MobiusHD® aiming at amplifying the 
BAT response by increasing wall strain in the carotid sinus. Initial results 
have been published in the previous year for 30 patients [21], and controlled 
trials are currently on the way. 
In addition to the indication TRH, the Barostim neo™ is concurrently eval-
uated for its efficacy and safety in the treatment of heart failure. Initial six 
months results from the ongoing trials have already been published, yet evi-
dence for this indication is yet too limited to draw conclusions on benefits or 
harms [28], thus, an assessment of this indication was considered premature.  
BAT for the treatment of TRH remains a controversially discussed therapy, 
not only due to the lacking data on efficacy and safety but also due to diffi-
culties to delineate TRH to other causes of uncontrolled hypertension, such 
as secondary causes, and pseudo-resistance [51]. Likewise, the actual preva-
lence of TRH is highly disputed [4]. Consequently, establishing which patient 
population could actually benefit from the intervention remains undefined. 
To overcome the diagnostic barriers, AMBP measurements received a prom-
inent placement in the diagnosis algorithm, yet it is unclear how often it is 
applied outside of clinical trials in daily practice. (see also applicability tab-
le Table A-6).  
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MobiusHD® – Gerät  
zur Stimulation von 
Barorezeptoren mittels 
Stents – nur vorläufige 
Ergebnisse verfügbar 
laufende Evaluation  
von Barostim neo™ bei 
Herzinsuffizienz 
BAT bei TRH auch 
umstritten aufgrund 
diagnostischer 
Abgrenzung der echten 
Therapieresistenz; 
unklar welche 
PatientInnen von BAT 
profitieren 
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Furthermore, a major obstacle to control hypertension is poor adherence to 
hypertensive therapy. Therapy adherence is seldomly assessed during the 
cause of a clinical trial, and if, mostly by means of patient-reported question-
naires rather than urine analysis or other objective measures. An increase or 
decrease in therapy adherence during the trials could thus be a major con-
founder of the trial results. Therapy adherence is expected to be improved 
when patients receive an interventional procedure, yet, the opposite was sug-
gested in a recent study on renal denervation, indicating a decreased adher-
ence after the intervention [52]. Furthermore, the lacking assessment of ther-
apy adherence could lead to inclusion of patients with pseudo-resistant hy-
pertension rather than true TRH, who would not necessarily benefit from the 
treatment. Future clinical studies should thus require proven therapeutic ad-
herence as inclusion criteria. 
In conclusion, despite the strong physiological rationale of the baroreflex ac-
tivation, BAT has not conclusively provided robust evidence for its benefit and 
safety. By contrast, the only comparative data on the first generation device 
was not able to establish a meaningful benefit for patients. For the new gen-
eration device, evidence does not suffice to conclude on effectiveness or safe-
ty. Future clinical trials should assess BP reduction based on AMBP meas-
urements, and include monitoring of therapy adherence. More importantly, 
apart from a reduction in BP emerging technologies on TRH need to prove if 
they provide a benefit in the long-term reduction of CV events.  
 
Therapieadhärenz als 
wesentliche Prämisse 
bei Behandlung von 
Bluthochdruck – kaum 
direkte Erhebungen in 
Studien  
 
fehlende 
Einschätzungen zu 
Therapieadhärenz 
können Fokus von BAT-
Zielgruppen verfälschen 
Conclusio: 
unzureichende Evidenz 
bzgl. Wirksamkeit und 
Sicherheit von BAT bei 
TRH; 
Bedarf an Studien mit 
Erhebung von 
Therapieadhärenz und 
Langzeitergebnisse bzgl. 
kardiovaskulärer 
Ereignisse erforderlich  
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
x The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove, that the assessed technology 
BAT is more effective than, and as safe as the standard management for TRH. 
No comparative studies on the effects of BAT compared to standard therapy 
were available. Furthermore, comparative evidence on the only marketed de-
vice Barostim neo™ is still lacking. RCTs and controlled studies on the sec-
ond generation device could allow assessment of actual efficacy and safety for 
patients, if patient-relevant outcomes, such as a decrease in the number of CV 
events, is assessed.  
The re-evaluation is recommended in 2020, if evidence from RCTs has be-
come available. 
Ongoing research 
The Barostim neo™ Pivotal Trial, a non-blinded RCT comparing BAT to 
standard management was said to be published in 2015 and postponed to 
September 2017. However, the results of this RCT on 310 patients are still 
pending.  
As the first trial not funded by the manufacturers, an RCT conducted by sev-
eral universities in Norway and Sweden has been initiated in 2015. The Nor-
dic BAT Study includes 100 patients with TRH, is double blinded and com-
pares BAT to the sham procedure. Its primary completing date is November 
2020. Furthermore, the ESTIM-rHTN trial, a randomised medico-economic 
study assesses economic efficacy of BAT compared to standard therapy in 128 
patients with TRH. This is the first evaluation of BAT compared to standard 
therapy, and includes a comparison of the number of CV events, yet as sec-
ondary outcome measure.  
In addition to the indication of TRH, BAT is currently evaluated as thera-
peutic option in patients with heart failure (NYHA Class III). This pivotal 
trial on Barostim Therapy for Heart Failure (BeAT-HF) enrolled 800 partic-
ipants and aims at FDA approval (estimated completion date 2021).  
unzureichende Evidenz 
bzgl. Überlegenheit von 
BAT gegenüber 
Standardtherapie  
bei TRH 
neuerliche Evaluation in 
3 Jahren empfohlen  
noch ausständiger RCT 
mit 310 PatientInnen zu 
Barostim neo™  
weiterer laufender RCT 
in Skandinavien – 
Ergebnisse für 2020 
erwartet 
 
ökonom. Evaluation 
laufend 
Trial zu BAT bei 
Herzinsuffizienz – 
Ergebnisse für 2021 
erwartet 
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A second procedure targeting the baroreceptors for the treatment of TRH, the 
MobiusHD®, is also currently investigated within the CALM studies. The 
CALM-Start, an RCT including 110 patients has an estimated study comple-
tion date in December 2019.  
Details on these ongoing RCTs on BAT can be found in Table A-7. 
 
 
MobiusHD®  
(BAT Stimulation  
auf Stents-Basis) in 
laufenden CALM 
Studien untersucht 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Baroreceptor activation therapy: Results from randomised, controlled trials 
Author, year Bisognano, 2011 [12] Beige, 2017 [8] 
Country USA Germany 
Sponsor CVRx Inc CVRx Inc 
Intervention/Product Rheos® system (CVRx) Barostim neo™device (CVRx) 
Comparator device ON vs OFF device ON vs OFF 
Study design double-blind randomised controlled trial double-blind, randomised cross-over trial 
Trial Number/Name NCT00442286, Rheos Pivotal Trial Barostim neo™withdrawal study 
Number of pts 265 randomised(plus 55 patients open label, 2 patients explant)  16 
Allocation randomisation in 2:1 ratio: Group A (n=181) activation one month after implant;  
Group B (n=84) delayed activation (at seven months post-implant)  
randomisation in BAT-On and BAT-Off group, groups changed 
after 4 weeks 
Population patients with TRH defined as office cuff SBP ≥ 160 mmHg DBP ≥80 mmHg as well as a  
24-hour ambulatory SBP ≥ 135 mmHg despite at least one month of maximally tolerated 
therapy with at least three antihypertensive medications, of which at least one  
must be a diuretic 
patients with implanted BAT between 2010 and 2014; 
preimplant condition was TRH (office SBP>140mmHg or 
130 mmHg if CKD, despite maximally tolerated therapy 
with at least three antihypertensive medications, of which 
at least one must be a diuretic 
Inclusion criteria  ≥21 years <80 years 
 have been assessed with bilateral carotid bifurcations that are easily interrogated  
by carotid duplex ultrasound and are below the level of the mandible. 
 must have completed the drug compliance questionnaire and have been judged  
to be compliant with medications. 
 for subjects with prior bariatric surgery: ≥1 year post-surgery, at a stable weight. 
 not pregnant 
 must be an appropriate or reasonable surgical candidate. 
 have signed a CVRx approved informed consent form for participation in this study 
 ≥18 years 
 exclusion of secondary causes of hypertension 
 exclusion of pseudo-resistance by ambulatory BPM 
 drug adherence was evaluated by directly observed  
therapy and/or urine medication analysis 
 not pregnant 
 no change in antihypertensive treatment for at  
least 4 weeks 
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Author, year Bisognano, 2011 [12] Beige, 2017 [8] 
Exclusion criteria  hypertension secondary to an identifiable and treatable cause other than sleep apnea 
 prior surgery, radiation, or endovascular stent placement in either carotid sinus region 
 known or suspected baroreflex failure or autonomic neuropathy 
 arm circumference greater than 46 cm and/or body mass index of greater than 45; 
 currently taking an imidazoline receptor agonist 
 unable or unwilling to fulfil the protocol medication compliance and follow-up requirements. 
 active infection within the last month. 
 enrolled in another concurrent clinical trial, without prior approval of CVRx 
 comorbidities: significant cardiac bradyarrhythmias; chronic atrial fibrillation; significant 
orthostatic hypotension; organ or hematologic transplant; myocardial infarction, unstable 
angina, syncope, or cerebral vascular accident within the past 3 months; carotid athero-
sclerosis producing a 50% or greater reduction in linear diameter (determined by ultrasound 
or angiographic evaluation as determined within 6 months of enrollment in the trial); 
ulcerative plaques in the carotid artery as determined by ultrasound or angiographic 
evaluation; severe CKD as defined by:Currently undergoing dialysis or dialysis is planned 
within 3 months of the implant date;eGFR of ≤30 ml/min/1.73m²; clinically significant cardiac 
structural valvular disease; clinically significant reactive airway disease, chronic obstructive 
pulmonary disease, and/or primary pulmonary hypertension; uncontrolled comorbid medical 
condition that would adversely affect participation in the trial; clinically significant 
psychological illness that would prohibit the subject’s ability to meet the protocol 
requirements; co-morbid condition that reduces life expectancy to less than one year 
 untreated secondary hypertension 
 carotid artery stenosis > 70% 
 SBP < 120 mmHg 
 major cardiovascular events within previous 6 months: 
acute myocardial infarction, unstable angina, stroke, 
transitory ischemic attack 
Age of patients (yrs)  53.7 ±10.5 (n=181) vs 52.4 ±9.8 53.5±16.1 (n=8) BAT off-on ITT vs 59.1 ±13 BAT on-off ITT 
Sex (% female) 65 (36%) vs. 38 (45%) 7 (87%) vs 6 (66%) 
Follow-up (months) mean: 21 ±8 months; 463 person-years of follow-up 8 weeks 
Loss to follow-up, n (%) 17 (9) vs 6 (7) 4 (25) 
Primary outcome 
measures 
 acute efficacy: % of patients with > 10mmHg reduction in office cuff SBP [Time Frame: 
6 months post-activation] superiority margin of 20%. 
 sustained efficacy: % of group A (Rheos® Device On) patients who maintain  
a 10 mmHg drop in SBP at 12 mo post-activation; response at 12 mo is at least 
 50% of the response at 6 mo post-activation. 
 BAT safety: therapy-related Adverse Event-free rate 
 device safety: major hypertension-related and Serious Device-related  
Adverse Event-free rate 
 procedural safety: Serious procedure- or system-related Adverse Event-free rate 
 systolic automated office BP should increase by  
more than 35 mmHg (SD 25 mmHg) when BAT is turned  
off for 4 weeks 
Mean BP medications 5.2 vs 5.2 4.7 vs 5.67 
BP mmHg at baseline 
(office BP) 
systolic: 169 ±26 vs 168 ±24 
diastolic: 101 ±17 vs 100 ±14 
(after previous BAT implantation) systolic:  
BAT off-on 135± 14 vs BAT on-off 142 ±44 
diastolic: 75 ±12 vs 90 ±22  
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Author, year Bisognano, 2011 [12] Beige, 2017 [8] 
Outcomes 
Efficacy 
Acute efficacy 
(proprotion of subjects 
with >10mmHg drop, 
20% superiority margin) 
at 6 mo: 54% vs 46% p=0.97 no patient had increase >35 mmHg after BAT off  
Sustained efficacy 
(>10mmHg drop at  
12 months, at least 50% 
of 6 months reduction) 
88% at 6 months (p<0.001) - 
Mean change in office SBP at 6 months:16 ±29 mmHg vs 9 ±29 mmHg (p=0.08) at 4 weeks: BAT off vs BAT on 10 mmHg  
Mean change in  
24-h ambulatory BP 
- at 4 weeks: ABP BAT off vs BAT systolic by 10 ±4 and  
diastolic 8 ±3  
% of patients SBP  
<140 mmHg 
at 6 months: A: 40% vs B 22% (p=0.005) 
at 12 months: A: 52% vs B: 51% (p=0.7) 
- 
Quality of life - - 
Number of CV events -  
Number of anti-
hypertensive medicines 
- none 
Saftey 
Mortality at 12 months: 4  - 
Number of SAE n, (%) Procedural: 68 (25.5) 
surgical complications 13 (4.8) 
Nerve injury with residual deficit 13 (4.8) 
Transient nerve injury 12 (4.4) 
- 
Device: 34 (12.8) 
Hypertension-related stroke 6 (2.3) 
- 
Number of BAT AE Hypertensive crisis: A 9 (5) vs 7 (8.3) - 
Procedure-related AE in % 30 days: event free rate of 74.8% , p=1.0 - 
BAT AE in % therapy-related event free rate of 91.7% vs 89.3% (p<0.001) - 
Device safety in % event-free rate of 87.2% (p<0.001) - 
Device explantation 2 - 
Abbreviations: AE = adverse event, BAT = baroreceptor activation therapy, BP = blood pressure, CKD = chronic kidney disease, CV = cardio-vascular, ITT = intension to treat,  
SAE = severe adverse event, SBP = systolic blood pressure, SD = standard deviation, TRH = treatment-resistant hypertension, yrs = years  
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Table A-2: Baroreceptor activation therapy Results from observational studies 
Author, year Scheffers, 2010 [11] de Leeuw, 2017 [10] Hoppe, 2012 [7] Wallbach, 2016 [5] Wallbach, 2015 [6] 
Country Multi-Center (Netherlands, 
Switzerland, Germany, Latvia, Poland) 
The Netherlands Austria Germany Germany 
Sponsor CVRx CVRx CVRx Grant support 
(authors received grant 
support from CVRx) 
CVRx 
Trial Name DEBuT-HT Rheos Feasibility trial, 
DEBuT-HT Trial, Rheos 
Pivotal trial 
Barostim neo™trial - - 
Intervention/Product Rheos® system CVRx Rheos® system CVRx Barostim neoTM CVRx Barostim neoTM CVRx Barostim neoTM CVRx 
Comparator Before-after Before-after Before-after Before-after Before-after 
Study design Multi-centre, prospective, single arm, 
open-label 
Open-label follow-up of 
[11, 12] 
Single-arm, open-label study Prospective observational 
study 
Prospective observational 
study (pre-specified 
subanalysis) 
Number of pts 45 (42 analysed) 383 30 51 (44 analysed) 30 (25 analysed) 
Inclusion criteria BP ≥160/90 mmHg despite ≥ 3 
antihypertensive agents including 
diuretic; compliant with medications; 
>21 years of age;  
Not described 
(described in original 
studies) 
Patients with resistant HTN 
(SBP ≥140 mm Hg) despite 
being prescribed at least 3 anti-
hypertensive medications 
including a diuretic and on 
stable medication (defined as 
no more than a 100% increase 
or 50% decrease in any one 
medication other than a 
diuretic during 4 weeks 
before qualifying BP 
measurements); compliant 
with medications;  
Office SBP ≥140 mm Hg, 
despite at least 3 antihyper-
tensive medications including 
a diuretic;  
age ≥ 18 years; all patients 
involved in this study were 
treated for HTN for at  
least 1 year 
Patients fulfilling diagnosis 
of resistant hypertension 
with BP ≥140/90 mm Hg  
and optimal therapy for 
secondary reasons were 
included.  
Exclusion criteria  Baroreflex failure or significant 
orthostatic hypotension 
 Cardiac bradyarrhythmias or chronic 
atrial fibrillation 
 carotid atherosclerosis determined by 
ultrasound or angiographic evaluation 
with a stenosis of greater than 50%.  
 prior surgery or radiation in either 
carotid sinus region  
 implanted electrical medical devices 
such as cardiac pacing, defibrillation or 
neurologic stimulation systems.  
 pregnancy  
 dialysis  
Not described 
(described in original 
studies) 
HTN secondary to an 
identifiable and treatable 
cause other than sleep 
apnea, known or suspected 
baroreflex failure or 
autonomic neuropathy, and 
myocardial infarction, 
unstable angina, syncope, or 
cerebral vascular accident 
within 3 months before 
implant.  
 Pregnancy 
 untreated secondary 
cause of HTN 
 acute myocardial 
infarction 
 unstable angina 
 stroke, or transitory 
ischemic attack within the 
previous 6 months 
 White-coat hypertension 
was excluded by 24-h 
ambulatory BP monitoring 
(ABPM).  
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Author, year Scheffers, 2010 [11] de Leeuw, 2017 [10] Hoppe, 2012 [7] Wallbach, 2016 [5] Wallbach, 2015 [6] 
Exclusion criteria 
(continuation) 
 hypertension secondary to a 
treatable cause  
 clinically significant cardiac valvular 
disease  
 unable to comply with protocol 
requirements 
 unlikely to survive the protocol 
follow-up period  
 enrolled in another concurrent 
clinical trial 
   Anatomic exclusion 
criterion was stenosis of the 
carotid artery >70% 
(routinely assessed in all 
patients by ultrasound and 
duplex sonography using 
North American 
Symptomatic Carotid 
Endarterectomy Trial 
[NASCET] criteria). 
 
Age of patients (yrs) 54 ±9 53 ±10  57 ±12 57 ±12 61 ±9 
sex (% female) 19 (42) 153 (40) 16 (53) 23 (52) 14 (56) 
Follow-up (months) 3 months, 1 year, 2 years 3 months - 6 years  3 months, 6 months At 6 months At 6 months 
Loss to follow-up,  
n (%) 
8 (17)  
26 subjects completed 1 year; 17 
completed 2 year follow-up 
142 (37)  
34 (8) within the 1st 
year 
0 (0) 7 (14) patients were 
excluded from analyzes 
because of missing or 
insufficient follow-up ABPM 
data (1 patient died because 
of a pneumonic sepsis and 6 
patients refused ABPM) 
5 (17) were excluded from 
the analysis: 2 patients with 
atrial fibrillation as well as 
another 3 patients (1 patient 
died due to pneumonic sepsis, 
1 patient failed follow-up 
visit and in one patient 
quality index was < 80 %).  
primary outcome 
measures 
 Safety by evaluating all AE and 
procedure related AE rate 
 10 mmHg decrease from baseline  
(= 1-month office BP) in SBP after  
three months of incrementally 
optimized therapy 
 Office SBP;  
 safety, AE 
 Office SBP;  
 all system- and procedure-
related complications 
 Change in systolic  
24-hour BP;  
 Change in carotid-to-
femoral PWV (PWVcf), 
central BP, PP, and Aix  
BP medications 
(mean, SD) 
5 (3-9) 5 (3-12) 6.1 ± 2.7 6.5 ± 1.5 6.6 ± 1.7 
BP mmHg at baseline  
(office BP) 
SBP:179 ±29 
DBP: 105±22 
SBP: 179 ±24 
DBP: 103 ±16 
SBP:172 ±20 
DBP: 100±14 
SBP:171 ±24 
DBP: 91 ± 18 
SBP:160 ± 27 
DBP: 83 ± 17 
Outcomes 
Efficacy 
Mean change in  
office BP 
12 months (n=26): SBP -21 ±6 
(p<0.001) 
DBP -20 ±4 (p<0.001) 
24 months (n=17): SBP -33 ±8 
(p=0.001) 
DBP -22 ±6 (p=0.002) 
12 months (n=335) 
SBP: ~-32; DBP ~-12 
24 months (n=299) 
SBP: ~-30; DBP ~-12 
3 years (n=278) 
SBP:~-32; DBP~-12 
6 years (n=48) 
SBP ~-33; DBP~-13 
6 months (n=30) 
SBP: -26 ± 4 
(p<0.01) 
6 months (n=44) 
SBP: -20 ± (28 – 12) 
(p<0.01); 
DBP: -9 ± (-13 – 4) 
(p<0.01) 
Mean not calculated 
6 months (n=25) 
SBP: 143 ± 27; DBP: 97 ± 18 
(p<0.01) 
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Author, year Scheffers, 2010 [11] de Leeuw, 2017 [10] Hoppe, 2012 [7] Wallbach, 2016 [5] Wallbach, 2015 [6] 
Mean change in  
24-h ambulatory BP 
12 months (n=15):  
SBP -13 ±3 (p<0.001) 
DBP -8 ±2 (p<0.001) 
24 months (n=8):  
SBP -24 ±8 (p=0.017);  
DBP -13 ±5 (p=0.049) 
- - 
(Lack of ambulatory  
BP measurement considered 
as a study limitation) 
Mean not calculated  
Baseline: SBP: 148 ± 17;  
DBP: 82 ± 13 (p<0.01) 
At 6 months: SBP: 140 ± 23; 
DBP: 77 ± 15 (p<0.01) 
- 
% of patients SBP 
<140 mmHG 
- - 43 at 6 months - - 
Quality of life - - - - - 
Number of CV events - - - - - 
Number of 
antihypertensive 
medicines 
No significant changes 27% (n=129) from 
median of 6 to 3 
34% (n=129) no change 
39% (n=149) increase 
from median of 5 to 7 
No significant changes Antihypertensives could be 
reduced significantly to  
6.0 ± 1.8 (p=0.03) 
No significant changes 
Saftey 
Mortality Angioneurotic oedema (n=1),  
6 days post-operative 
- - - - 
SAE n, (%) 8 (20) 335 (246)  
(n=136)  
relatable to procedure/ 
device/BAT: 26 (19) 
-  Contralateral stroke 1 (2) - 
Procedure related  
AE SAE, n, (%) 
7 (16) 
angioneurotic edema (n=1) 
explantations due to infection (n=3) 
perioperative stroke (n=1) 
tongue paresis (injury of hypoglossal 
nerve) (n=1) 
pulmonary edema (n=1) 
16 (12) 
CV events (n=13) 
other (n=3) 
Perioperative events: 3 (10) 
Device pocket hematoma 
(n=1) 
Self-inflicted wound 
complication (n=1) 
Intermittent pain lateral of 
device system (n=1) 
20 (45) 
minor procedure-related 
complication (n=10).  
disturbance of wound 
healing (n=5)  
a postoperative hematoma 
(n=4)  
a hematoma of the vocal cord 
seemed transiently after 
device implantation (n=1)  
- 
Device related  
AE SAE, n, (%) 
1 (2) 
movement of IPG, re-operation 
9 (6) 
related to IPG (n=5) 
lead-related (damage/ 
migration/tension/ 
haematoma) (n=4) 
Long-term event: 1 (3) 
Intermittent pain near the 
device system (n=1) 
2 (5) 
movement/ pain of the IPG 
(resulting in the need for 
reposition) (n=2) 
- 
Device explantations 
n, (%) 
3 (6) 15 (11) 0 (0) 0 (0) - 
Abbreviations: AE = adverse event, BAT = baroreceptor activation therapy, BP = blood pressure, CKD = chronic kidney disease, CV = cardio-vascular, ITT = intension to treat,  
SAE = severe adverse event, SBP = systolic blood pressure, SD = standard deviation, TRH = treatment-resistant hypertension, yrs = years)  
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57 
Risk of bias tables and GRADE evidence profile 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement, a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA 
[53] and in the Guidelines of EUnetHTA [54, 55].  
Table A-3: Risk of bias – study level (randomised studies), evaluated with Cochrane Risk of Bias tool, 2011 [18] 
Trial 
Adequate generation  
of randomisation 
sequence 
Adequate 
allocation 
concealment 
Blinding 
Incomplete 
outcome data 
Selective outcome 
reporting unlikely 
No other aspects 
which increase the  
risk of bias 
Risk of bias – 
study level Patient Treating Physician 
NCT00442286, 
Rheos Pivotal Trial 
Unclear Unclear Yes Yes Yes Yes Yes low 
Beige et al, 2017 Unclear Yes Yes Yes No1 No1 No2 High 
1 statistically relevant comparisons not reported; the study fails to report on safety-related outcomes and adverse events; 2 had unexplained baseline imbalances 
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Table A-4: Risk of bias – study level (case series), IHE checklist [47] 
Study reference/ID 
Scheffers, 
2010 [11] 
de Leeuw, 
2017 [10] 
Hoppe,  
2012 [7] 
Wallbach, 
2016 [5] 
Wallbach, 
2015 [6] 
Study objective 
1. Was the hypothesis/aim/objective of the study clearly stated? Yes No  Yes Yes Yes 
Study design 
2. Was the study conducted prospectively? Yes No  Yes Yes Yes 
3. Were the cases collected in more than one centre? Yes Yes Yes Unclear Unclear 
4. Were patients recruited consecutively? Unclear Unclear Unclear Unclear Unclear 
Study population 
5. Where the characteristics of the participants included in the study described? Yes No  Yes Yes Yes 
6.  Were the eligibility criteria (inclusion and exclusion criteria) for entry into the study clearly stated? Yes No  Yes Yes Partial 
7. Did participants enter the study at a similar point in the disease? Yes Unclear  Unclear Unclear Unclear 
Intervention and co-intervention 
8. Was the intervention clearly described? Yes No  Yes Yes Yes 
9. Were additional interventions (co-interventions) clearly described? Yes No  Yes Yes Partial 
Outcome measure 
10. Were relevant outcome measures established a priori? Yes No  Yes Yes No 
11. Were outcome assessors blinded to the intervention that patients received?.  No No  No No No 
12. Were the relevant outcomes measured using appropriate objective/subjective methods?  Yes Partial  Partial Partial No 
13. Were the relevant outcomes measured before and after intervention? Yes Yes  Yes Yes Yes 
Statistical Analysis 
14. Were the statistical tests used to assess the relevant outcomes appropriate? Yes Yes  Yes Yes Unclear 
Results and Conclusions 
15. Was follow-up long enough for important events and outcomes to occur?  Yes Yes  No No No 
16. Was the loss to follow-up reported? Yes Unclear  Yes Yes Unclear 
17. Did the study provide estimates of random variability in the data analysis of relevant outcomes?  Yes Partial Yes Yes Yes 
18.  Were adverse events reported? Partial Partial Yes Yes No 
19. Were the conclusions of the study supported by results? No No  Yes No No 
Competing interest and source of support 
20. Were both competing interest and source of support for the study reported? Yes Yes  Yes Yes Yes 
Overall Risk of bias Low High Low Low High 
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Table A-5: Evidence profile: efficacy and safety Baroreceptor Activation Therapy  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies Study design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Barostim 
Activation 
Therapy 
standard 
therapy  
(or BAT-off) 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Reduction of systolic 24-hour AMBP 
1  observational 
studies  
serious a not serious  not serious  serious b none  44  0  -  mean  
8 mmHg lower 
(2 lower to 14 
lower)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Reduction of office SBP 
2  observational 
studies  
serious a not serious  not serious  serious b none  74  0  -  mean  
23 mmHg lower  
(0 to 0 )  
⨁◯◯◯ 
VERY LOW  
IMPORTA
NT  
Reduction in the number of CV events – not reported 
-  -  -  -  -  -  -  -  -  -  -  -  CRITICAL  
Procedure-related serious adverse events 
2  observational 
studies  
serious a not serious  not serious  serious b none  24 events in 74 patients  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
Device-related serious adverse events 
2  observational 
studies  
serious a not serious  not serious  serious b none  4 events in 74 patients  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
a not blinded, no adjusted for confounding  
b small sample size, wide confidence intervals  
c First generation device, different operating mechanism and safety profile; not in clinical use anymore  
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
Abbreviations: AMBP = Ambulatory blood pressure, CI = confidence interval, SBP = systolic blood pressure 
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Applicability table 
Table A-6: Summary table characterising the applicability of BAT studies 
Domain Description of applicability of evidence 
Population The main body of evidence assessed patients with resistant hypertension. TRH is difficult to diagnose 
due to the possibility of secondary reasons for hypertension, or apparent resistant hypertension, due 
to lacking compliance or therapy adherence. While most studies states to have diagnosed TRH by use 
of AMBP and office BP to rule out white coat hypertension, therapy adherence was not assessed by 
most studies. It is, therefore, possible that the study population is overestimating TRH prevalence. 
The trials excluded several comorbidities, which are more common in patients with TRH patients.  
It is unclear whether BAT is safe to use in patients with these comorbidities.  
Intervention The studies described BAT as add-on therapy for the treatment of TRH. While the implantation of 
the stimulation device was explained in almost all studies, changes in additional therapeutic regimens 
were not explicitly mentioned by the studies. Physicians were free to change the anti-hypertensive 
dosages and medication, which was not adjusted for potential confounding.  
Comparators The included studies described BAT compared to a sham procedure for the first generation device. 
No comparative evidence was available for the second generation device, despite European market-
authorization since 2011.  
For neither of the devices, studies compared BAT in relation to standard therapeutic management, 
thus benefits in comparison to standard therapy in terms of reduction of CV events could not be 
evaluated.  
Outcomes The most critical outcome for the assessment of a potential benefit of the BAT is a reduction in the 
number of CV events, as compared to standard therapy. This outcome was not evaluated by any of 
the studies.  
Furthermore, it is recommended to assess a reduction in BP by use of AMBP measurements rather 
than office BP measurements, to allow evaluating day-night differences, and overall BP reduction of 
a day, rather than a single measurement once a day. Only one study on the second generation device 
including 44 patients assessed AMBP.  
Setting While the studies on the first generation device reflected geographical diversity, the studies on the 
second generation device were all based in Europe, two of them in Germany and one in Austria. The 
geographical focus of the published literature is in Germany and the Netherlands. However, ongoing 
trials from Nordic countries and France indicate European diversity of study settings. Data from the 
US context is only available from the first generation device. Evidence from other high-income 
countries is lacking.  
The procedures took place in hospital operating rooms, which reflects the clinical setting where the 
technology is deployed.  
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List of ongoing randomised controlled trials 
Table A-7: List of ongoing controlled trials of baroreceptor activation therapy for resistant hypertension 
Identifier/ 
Trial name 
Study design Enrollment Status Primary  
completion date 
Conditions  Intervention/ 
Comparison 
Primary Outcome Sponsor 
NCT02572024/  
The Nordic BAT 
Study 
Allocation: Randomize, 
Intervention Model:  
Parallel Assignment, Masking: 
Double (Investigator, 
Outcomes Assessor),  
Primary Purpose: Treatment 
100 Recruiting 11/2020 Resistant 
Hypertension 
Device: 
BAT|Other: 
Placebo 
 Change in systolic 
ambulatory BP in response 
to BAT therapy 
 Change in home BP in 
response to BAT therapy 
 Change in office blood 
pressure in response  
to BAT therapy 
 Change in autonomic 
function in response to 
BAT therapy 
Helsinki University 
Central Hospital, 
Skane University 
Hospital|Sahlgrenska 
University Hospital, 
Sweden|Karolinska 
Institutet|Odense 
University Hospital| 
University of Oslo| 
Helsinki University 
NCT01679132 
BAROSTIM NEO 
HTN Pivotal Trial 
Allocation: 
RandomizedIntervention 
Model: Parallel Assignment; 
Masking: None (Open-Label); 
Primary Purpose: Treatment 
310 Active, not 
recruiting 
09/2017 Uncontrolled 
Hypertension 
Device: Neo 
Baroreflex 
Activation 
Therapy 
System|Other: 
Standard of care 
medical 
management 
only 
 Primary Safety 
Objective 
 Primary Efficacy 
Industry CVRx, Inc. 
NCT02364310, 
ESTIM-rHTN 
Economic Evaluation; 
Allocation: Randomized; 
Intervention Model: Parallel 
AssignmentMasking: None 
(Open Label), Primary 
Purpose: Treatment 
128 Recruiting 11/2018 Hypertension Device: BAT with 
Barostim neo™ 
12th month SBP (mmHg) 
measured on ABPM, 
adjusted on baseline SBP, 
to compute the 
incremental  
cost-effective ratio  
Central Hospital, 
Nancy, France 
NCT03179800 
CALM- 2 
Allocation: Randomized; 
Intervention Model: 
Crossover Assignment; 
Masking: Triple (Participant, 
Care Provider, Outcomes 
Assessor); Primary Purpose: 
Treatment 
300 Recruiting 05/2020 Resistant 
Hypertension 
Device: 
MobiusHD|Other: 
Sham 
Implantation 
Primary Effectiveness 
Endpoint – Change in 
mean 24-hr sABP from 
baseline to 180-day 
Industry Vascular 
Dynamics, Inc. 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: Baroreflex activation for treatment-resistant hypertension 
Search Date: 06/12/2017 18:31:18.492 
ID Search 
#1 MeSH descriptor: [Hypertension] explode all trees 
#2 hypertens* (Word variations have been searched) 
#3 (high* or heighten* or rais* or elevat* or increas*) near blood pressure* (Word variations have been 
searched) 
#4 #1 or #2 or #3  
#5 resistant or resistent (Word variations have been searched) 
#6 #4 and #5  
#7 (resistant or resistent) near (hypertens* or ((high* or heighten* or rais* or elevat* or increas*) near blood 
pressure*)) (Word variations have been searched) 
#8 #6 or #7  
#9 MeSH descriptor: [Baroreflex] explode all trees 
#10 baro*reflex (Word variations have been searched) 
#11 MeSH descriptor: [Pressoreceptors] explode all trees 
#12 presso*receptor* (Word variations have been searched) 
#13 Baro*receptor* (Word variations have been searched) 
#14 #9 or #10 or #11 or #12 or #13  
#15 stimul* or activat* (Word variations have been searched) 
#16 MeSH descriptor: [Electric Stimulation Therapy] explode all trees 
#17 #15 or #16  
#18 #14 and #17  
#19 BAT:ti,ab,kw  
#20 BaroStim (Word variations have been searched) 
#21 Rheos (Word variations have been searched) 
#22 CVRx (Word variations have been searched) 
#23 (baro*receptor* or presso*receptor* or baro*reflex* or caroti*) near (stimul* or activat*) (Word variations 
have been searched) 
#24 #18 or #19 or #20 or #21 or #22 or #23  
#25 #8 and #24  
Total: 39 Hits 
 
 
Search strategy for CRD 
Search Name: Baroreflex activation for treatment-resistant hypertension 
Search Date: 06/12/2017  
ID Search 
1 MeSH DESCRIPTOR Hypertension EXPLODE ALL TREES 
2 (hypertens*) 
3 ((high* OR heighten* OR rais* OR elevat* OR increas*) NEAR blood pressure*) 
4 #1 OR #2 OR #3 
5 MeSH DESCRIPTOR Baroreflex EXPLODE ALL TREES 
Appendix 
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6 (baro*reflex*) 
7 MeSH DESCRIPTOR Pressoreceptors EXPLODE ALL TREES 
8 (presso*receptor*) 
9 (Baro*receptor*) 
10 MeSH DESCRIPTOR Electric Stimulation Therapy EXPLODE ALL TREES 
11 (BAT) 
12 (BaroStim) 
13 (Rheos) 
14 (CVRx) 
15 ((baro*receptor* OR presso*receptor* OR baro*reflex* OR caroti*) NEAR (stimul* OR activat*)) 
16 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 
17 #4 AND #16 
Total: 12 Hits 
 
 
Search strategy for Embase 
Search Name: Baroreflex activation for treatment-resistant hypertension 
Search Date: 06/12/2017  
No. Query Results 
#31 #12 AND #30 
#30 #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 
#29 ((baro*receptor* OR presso*receptor* OR baro*reflex* OR caroti*) NEAR/2 (stimul* OR activat*)):ti,ab 
#28 cvrx:df 
#27 rheos:dn,df 
#26 barostim:dn 
#25 bat:ti,ab 
#24 ‘baroreflex activation therapy’/exp 
#23 #19 AND #22 
#22 #20 OR #21 
#21 ‘electrotherapy’/exp 
#20 stimul* OR activat* 
#19 #13 OR #14 OR #15 OR #16 OR #17 OR #18 
#18 baro*receptor*:ti,ab 
#17 presso*receptor*:ti,ab 
#16 ‘pressoreceptor’/exp 
#15 baro*reflex:ti,ab 
#14 ‘carotid sinus pressoreceptor reflex’/exp 
#13 ‘pressoreceptor reflex’/exp 
#12 #10 OR #11 
#11 ‘treatment resistant hypertension’/exp  
#10 #8 OR #9 
#9 ((resistant OR resistent) NEAR/1 (hypertens* OR ‘high* blood pressure*’ OR ‘heighten* blood pressure*’ OR 
‘rais* blood pressure*’ OR ‘elevat* blood pressure*’ OR ‘increas* blood pressure*’)):ti,ab 
#8 #4 AND #7 
#7 #5 OR #6 
#6 resistent 
#5 resistant 
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#4 #1 OR #2 OR #3 
#3 ((high* OR heighten* OR rais* OR elevat* OR increas*) NEAR/2 ‘blood pressure*’):ti,ab 
#2 hypertens*:ti,ab 
#1 ‘hypertension’/exp 
Total: 390 Hits 
 
 
Search strategy for Medline 
Search Name: Baroreflex activation for treatment-resistant hypertension 
Search Date: 06/12/2017  
No. Query Results Results 
1 exp Hypertension/ 254,475 
2 hypertens*.mp. 492,259 
3 ((high* or heighten$3 or rais$3 or elevat$3 or increas$3) adj3 blood pressure*).mp. 61,786 
4 1 or 2 or 3 518,692 
5 resist#nt.mp.  414,308 
6 4 and 5 8,194 
7 (resist#nt adj (hypertens* or ((high* or heighten$3 or rais$3 or elevat$3 or increas$3) adj3 
blood pressure*))).mp. 
3,175 
8 6 or 7 8,194 
9 exp Baroreflex/ 5,931 
10 baro?reflex.ti,ab. 8,188 
11 exp Pressoreceptors/ 8,220 
12 presso?receptor*.ti,ab. 112 
13 Baro?receptor*.mp. 7,798 
14 9 or 10 or 11 or 12 or 13 18,240 
15 (stimul* or activat*).mp. 2,869,881 
16 exp Electric Stimulation Therapy/ 76,618 
17 15 or 16 2,903,276 
18 14 and 17 6,985 
19 BAT.ti,ab. 1,2451 
20 BaroStim.ti,ab. 16 
21 Rheos.ti,ab. 34 
22 CVRx.ti,ab. 11 
23 ((baro?receptor* or presso?receptor* or baro?reflex* or caroti*) adj2 (stimul* or 
activat*)).mp. 
2,276 
24 18 or 19 or 20 or 21 or 22 or 23 19,933 
25 8 and 24 264 
26 remove duplicates from 25 239 
Total: 239 Hits 
 
 

  
 
